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Breast cancer is the most common cancer in women worldwide, and is the second 
leading cause of cancer-related death in spite of significant advances in treatment and 
emphasis on early diagnosis. While treatment of localized disease is often successful, 
metastatic breast cancer, especially of the triple negative molecular subtype, carries a 
much poorer prognosis. The significant role of the immune system in the progression 
from localized to metastatic disease is becoming more and more appreciated. Tumor 
escape from immune surveillance and immune suppression in the tumor 
microenvironment have become therapeutic targets in addition to the traditional goals of 
directly killing tumor cells. A number of immune therapeutic strategies have been 
proposed and tested, but few have seen clinical application in the treatment of breast 
cancer. The development of successful breast cancer immunotherapeutic strategies 
depends on the rapid identification of immunogenic antigens, timely delivery of these 
antigens by the optimal vehicle to induce a robust immune response, and appropriate 
combination with other therapies such as adjuvants, innate immune therapies, and the 
current standard-of-care treatments. This will allow for more comprehensive targeting of 
the breast cancer immune regulatory network and likely lead to improved therapeutic 
success. In the following experiments, two immune therapies which address elements of 
this multipronged approach will be investigated. The models in which these therapies are 
tested for gross phenotypic effect are intended to bring basic murine models of 
experimentation closer to the patterns of future clinical application. The first of these 
iv 
 
therapies is emodin, a natural, small molecule compound derived from several Chinese 
herbs. Its immune modulatory properties have been demonstrated in a number of disease 
models, but our lab was the first to show that it is capable of attenuating breast cancer 
progression by blocking the interactions between tumor-associated macrophages and 
cancer cells. Here emodin is tested as an adjuvant therapy following primary tumor 
surgical removal for the purpose of preventing metastatic recurrence in a model of 
murine triple negative breast cancer. We show that trough interfering with TGF-β1 
signaling, emodin is capable of decreasing the ability of tumor cells to invade and 
establish themselves at metastatic sites, thereby reducing metastatic recurrence and 
increasing overall survival. In addition to its ability to disrupt the reciprocal signaling 
between tumor cells and macrophages, emodin’s low cost and proven low toxicity make 
it a promising innate immune therapy.  The second therapeutic strategy focuses on 
improving the effectiveness of dendritic cell-based therapeutic cancer vaccines. Our lab 
was the first to reveal the role of microRNA-155 (miR155) as a key regulator of dendritic 
cell function. Our previous work has shown that total-body knockout of miR155 
increased both tumor growth and metastasis in an orthotopic model of murine breast 
cancer. Our therapeutic goal is to increase the presence of miR155 in the immune cells of 
the tumor microenvironment, most importantly in dendritic cells. Here, total immune 
system overexpression of miR155 and a miR155-overexpressed DC vaccination therapy 
are shown to reduce breast tumor growth and metastasis by boosting cytotoxic T cell 
activity through it multiple positive effects on dendritic cell maturation and migration to 
tumor-draining lymph nodes. From the results detailed here, both of these strategies hold 
promise as valuable elements of future combination immune therapies for breast cancer. 
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1.1 BREAST CANCER 
The most prevalent non-skin malignancy worldwide is breast cancer. Though 
second to lung cancer in terms of mortality, its much higher prevalence makes it the most 
expensive malignancy to treat [1]. The annual cost is expected to rise to $20.5 billion by 
2020 [2]. 12.3% of women will be diagnosed with breast cancer at some point in their 
lives, and metastatic breast cancer remains largely incurable even with recent therapeutic 
advances [2]. Five-year survival of patients with metastatic disease is only 21% while 
that of patients with non-metastatic disease is 89-100%, and 1/3 of patients deemed 
metastasis-free at diagnosis develop distant metastasis after surgical removal of the 
primary tumor [3]. These sobering facts remain even as the overall breast cancer death 
rate has decreased by 36% from 1989 to 2012 in the United States [2]. This decrease has 
largely been due to increased emphasis on early detection and some improvements in the 
effectiveness of available therapies [4]. However, there is still a great need for further 
development of more effective therapies, especially for triple negative tumors, and to 
reduce the harmful side effects associated with systemic chemotherapy and radiotherapy, 
such as cardiomyopathy, peripheral neuropathy, neurocognitive dysfunction, decreased 
fertility, and the induction of secondary cancers among others [5]. Immune therapies 
present promising alternatives with a theoretically more targeted activity and more 
durable clinical response with fewer long-term negative effects. 
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1.2 BREAST CANCER CLASSIFICATION AND CHARACTERIZATION 
Human breast cancer is divided into two overarching categories based on whether 
or not the disease has spread; namely, in situ carcinoma, which consists of cellular 
abnormalities and resulting distortions of ductal and lobular tissue, and invasive 
carcinoma, which has breached the basement membrane of the glands from which it 
originated. The majority of clinically identified cancers are invasive, and prognosis is 
largely determined by staging and subtype [2].  
Staging is the extent to which the invasive carcinoma has spread at the time of 
diagnosis, and there are two widely used systems for quantifying this: the Surveillance, 
Epidemiology, and End Results (SEER) Summary Stage and TNM Staging. The TNM 
classification is most often used in clinical settings and is determined by the following 
three factors: how far the primary tumor has spread within the breast and adjacent tissues 
(T), the extent to which tumor cells have colonized draining lymph nodes (N), and the 
absence or presence of metastasis in distant organs (M) [6]. A stage of 0 to IV is then 
assigned based on the TNM assessment with 0 being in situ and IV being advanced 
metastatic disease.  
There are two major subtype classifications: histological, of which there are 21, 
and molecular, of which there are at least four [7, 8]. These molecular subtypes are most 
often determined by the presence or absence of hormone (estrogen and progesterone) 
receptors (HR+/HR-) and the overproduction of human epidermal growth factor (HER2). 
Conveniently these biological markers can also be used as therapeutic targets, and often 
to great effect, making certain molecular subtypes demonstrably more treatable than 
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others. These four subtypes are generally as follows: luminal A (HR+/HER2-), luminal B 
(HR+/HER2+), HER2-enriched (HR-/HER2+), and triple negative (HR-/HER2-) [9-12].   
Luminal A is the most common (74% of tumors), least aggressive, and the most 
quickly responsive to therapy, especially hormonal therapy, and is associated with the 
best prognosis of the four subtypes [13]. Luminal B tumors make up about 10% of breast 
cancers and are more aggressive than luminal A, often containing a high proportion of 
actively dividing cells [14]. With the recent advent of HER2-targeted therapies in 
addition to hormone therapies, the prognosis for luminal B tumors is improving. HER2-
enriched tumors make up only 4% of all diagnosed breast cancers, and tend to be very 
aggressive with a poor prognosis in the absence of HER2-targeted therapies, which have 
proven highly effective [13]. Triple negative cancers are the most difficult to treat. Triple 
negative breast cancer is more common in younger women, African Americans, and 
those with BRCA1 gene mutations, though recent studies have shown that the increased 
prevalence among African Americans is not related to BRCA1 [15]. The vast majority 
(~86%) of triple negative breast cancer is basal-like based on gene expression profile in 
contrast to the other three molecular subtypes, none of which are more than 11% basal-
like [16]. Basal-like breast cancers are so named because they express a pattern of 
markers consistent with the basal layer of the breast ductal epithelium [17]. With no ER, 
PR, or HER2 to target, clinicians are limited to surgical resection, radiotherapy, and 
cytotoxic chemotherapy. There are currently few targeted therapies for triple negative 
tumors, and thus this breast cancer subtype has the least favorable short-term prognosis, 
but is the focus of a great deal of study in order to understand its molecular background 
and translate this to targeted therapy [13, 18-20].  
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1.3 BREAST CANCER TREATMENT 
Treatment regimens for breast cancer are largely determined by the stage and 
molecular subtype as well as patient characteristics, such as age and menopausal status 
[2]. In general tumors discovered at earlier stages merit some type of surgical 
intervention combined with adjuvant therapies to reduce the likelihood of recurrence. 
Successful treatment options for late-stage, metastatic disease are more limited, and 
systemic chemotherapies or targeted therapies are key due to the fact that removal of the 
primary tumor has little beneficial impact on overall survival once the cancer has spread 
[2].  
Surgical intervention often serves a dual purpose, to both remove the dysplastic 
tissue and aid in accurately staging the disease. The most common two surgical 
procedures currently performed are mastectomy (complete removal of the breast) and 
breast-conserving surgery (BCS), which involves removal of the tumor itself and a 
margin of normal tissue. Both BCS and mastectomy are often accompanied by removal 
of a few axillary lymph nodes, sentinel lymph node biopsy (SLNB), in order to determine 
staging, whether or not to perform further surgery, and to guide chemotherapy decision-
making [21]. Patients are increasingly opting for mastectomy over BCS even though 
long-term outcomes are very similar for these two interventions, while BCS does yield a 
higher rate of local recurrence [22-24]. Patient studies have found that this is because of 
reluctance to undergo radiation therapy, which is more often recommended with BCS, 
and patient fear of recurrence after less aggressive BCS surgery [25]. Modified radical 
mastectomy, removal of the entire breast and axillary lymph nodes, is also performed in 
some cases if patients elect to peruse this route, but the risk of lymphedema, severe 
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swelling of the arm due to impaired lymph drainage, discourages some, though there are 
successful physical therapies for this condition [26, 27]. Traditional radical mastectomies, 
in which the muscles of the chest wall are also removed, are very rarely performed and 
are not necessary to adequately remove most cancers. However, the rate of bilateral 
mastectomy, or contralateral prophylactic mastectomy (CPM) is increasing. While this 
does eliminate the risk of developing future breast cancer, it has not been shown to 
increase long-term survival and is more closely associated with a number of harmful 
outcomes including mortality [28-33].  
Radiation therapy often accompanies surgery, especially BCS or when a small 
number of tumor cells are found upon SNLB, and full axillary lymph node dissection is 
not performed [34, 35]. It employs appropriately shaped beams of ionizing radiation or an 
implanted radioactive source (brachytherapy) to damage the DNA of and kill tumor cells, 
often using intersecting low-energy beams to limit damage to adjacent tissue [2]. In the 
case of BCS, adjuvant radiation therapy has been demonstrated to reduce breast cancer 
recurrence by about 50% and the relative risk of death due to recurrence by about 20% 
[36]. The most common implementation is whole breast radiation for three to seven 
weeks [37]. Brachytherapy has been shown to be more likely to have complications, such 
as infection, and still requires a subsequent full mastectomy more often than whole breast 
external radiation, though any radiotherapy is not without side effects.  
The other common component of breast cancer treatment is systemic therapy, 
referring to any treatment to which the entire body is subjected due to its distribution via 
the circulation. This includes chemotherapy, targeted therapy, immunotherapy, and 
hormone therapy. These treatments are usually administered either before primary 
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surgical intervention (preoperative or neoadjuvant) or after (adjuvant). It is often 
advisable to attempt to shrink larger tumors via neoadjuvant therapy in order to reduce 
the complexity of resection. Additionally, systemic neoadjuvant therapy has been shown 
to be as effective as adjuvant therapy at increasing survival, and decreasing metastatic 
recurrence [38]. After all, the main purpose of adjuvant chemotherapy is to destroy 
disseminated cancer cells and micrometastases, and neoadjuvant therapy likely has a 
similar effect. Due to this ability to kill tumor tissue throughout the body, high stage, 
metastatic disease is primarily treated with systemic therapy, as primary tumor surgical 
resection has little impact on the total disease burden. The decisions about which 
systemic therapies are appropriate are governed by tumor stage, molecular subtype, and 
occasionally genetic panels such as Oncotype DX and PAM 50, which can help to predict 
the risk of metastatic recurrence [2].  
Traditional chemotherapies are more deadly to rapidly proliferating cells than 
more quiescent ones. This makes them generally more effective against more aggressive 
tumors such as those overexpressing HER2 and triple negative cancers [39]. 
Chemotherapy is the most commonly prescribed therapy for triple negative tumors 
regardless of stage due to the complete lack of targeted therapies, with platinum 
compounds, such as cisplatin, demonstrating clinical efficacy. However, recent massively 
parallel sequencing has revealed that triple negative breast cancer itself is highly 
heterogeneous and some forms may express molecules that could be potential therapeutic 
targets such as androgen receptors [40]. No systemic chemotherapy is free of potentially 
life-altering toxicities, driving the development of targeted/immune therapies to reduce 
this collateral morbidity [41].  
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The goal of hormone therapy is to either lower systemic levels of estrogen or 
block its pro-tumor effects. Hormone therapy is of course most effective on luminal 
tumors, especially luminal A tumors expressing both estrogen (ER+) and progesterone 
(PR+) receptors. Until recently it was not known why such “double positive” tumors 
were more susceptible to hormone therapy, because the progesterone receptor was not 
directly targeted by most therapies, and ER+/PR+ patients received the same treatments 
as ER+/PR- ones. Evidence now points to increased progesterone receptor activity 
naturally counteracting the estrogen-mediated proliferation, and progesterone receptor 
agonism may boost the effectiveness of estrogen receptor antagonism [42]. Compared to 
chemotherapies, hormone therapy is usually implemented for much longer after the 
primary surgical intervention takes place. Tamoxifen, a selective estrogen receptor 
modulator (SERM) and one of the most common hormonal therapies, when given for at 
least five years post-surgery, reduced the rate of recurrence by 40-50% over the 10-year 
period following surgery and reduced mortality by about 30% 15 years after diagnosis 
[43]. More recent studies have demonstrated that even longer use of tamoxifen yields 
even greater benefit [44, 45]. In addition to SERMs, aromatase inhibitors (AIs) are 
commonly used to treat HR+ breast cancer. The aromatase enzyme converts testosterone 
to estradiol and androstenedione to estrone, thus inhibiting this enzyme, reduces total 
available estrogens produced in the adrenal glands, but has no effect on ovarian estrogen. 
For this reason AIs are more effective in post-menopausal women and often considered 
an adjunct therapy to SERMs. These hormonal therapies, while effective for HR+ tumors, 
are not without side effects related to starving the body or specific tissues of estrogen 
stimulation such as menopausal symptoms and osteoporosis.  
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A number of targeted therapies are now available for tumors overexpressing 
molecules related to increased proliferative activity. Several of these target HER2; 
trastuzumab and pertuzumab are monoclonal antibodies against different regions of the 
HER2 protein. Trastuzumab has been demonstrated to reduce the risk of recurrence in 
early stage, HER2-enriched tumors by about 50% relative to chemotherapy alone [46]. 
Ado-trastuzumab emtansine is a combination molecule consisting of the same antibody 
found in trastuzumab and the chemotherapy drug emtansine (DM-1). The HER2 antibody 
preferentially carries what would be a systemic chemotherapy to the tumor, thus 
decreasing side effects and increasing the tumoricidal effect [47]. Other approved 
targeted therapies block cyclin-dependent kinases (CDKs) involved in cell proliferation 
and mTOR, a protein that promotes angiogenesis and proliferation, and there are many 
more currently in development [48-51]. A noteworthy issue with these therapies is that all 
of these targets are the body’s native molecules which are just aberrantly expressed in 
breast cancers, thus even these therapies are not targeted to only the tumor cells.   
1.4 CANCER IMMUNOTHERAPY 
The targeted therapies discussed in the previous section are all antibodies, and are 
thus referred to as passive immunotherapies [52]. Any directly tumor-targeting antibody 
or adoptive cell therapy is considered a passive immunotherapy, while cancer vaccines 
and directly immune modulatory antibodies (such as checkpoint blockade) are considered 
active immunotherapy [52]. The only immune modulatory antibody currently approved 
for the treatment of breast cancers with some genetic characteristics is pembrolizumab, a 
humanized IgG4 isotype antibody against lymphocyte PD-1. In 2017 the FDA approved 
the use of pembrolizumab for metastatic solid tumors with genetic anomalies such as 
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microsatellite instability and mismatch repair deficiency [53]. Two of the most significant 
reasons why the subset of tumors for which this drug can be used is so small are: (a) not 
all tumors express elevated levels of PD-L1 and (b) blocking the interaction between PD-
1 on leukocytes and PD-L1 fosters the immune-mediated destruction of the PD-L1 
expressing tumor, but also can induce severe autoimmunity resulting in conditions such 
as Crohn’s disease, lupus erythematous, and rheumatoid arthritis [54]. Other PD-1 and 
PD-L1 antibodies have shown promising results in breast cancer studies and several are 
currently undergoing breast cancer-specific clinical trials, but response rates remain at 
about 15-30% when used as a monotherapy. Modifications to PD-L1 antibodies, such 
glycosylation via B3GNT3 glycosyltransferase, have increased this response rate 
significantly, but so far only outside the clinical setting [55]. CTLA-4 blocking 
antibodies, such as ipilimumab, have been approved for some cancers, but not breast 
cancer, and present a higher risk for life-threatening autoimmunity than PD-1/PD-L1 
interference [56]. Several other checkpoint inhibitors have been investigated, and some, 
including TIM-3 blocking antibodies, have demonstrated potential to increase 
proliferation and cytokine release from tumor antigen-specific T cells, but none have 
been approved for clinical use [57, 58]. 
Another emerging immune therapy for solid tumors involves adoptive transfer of 
tumor specific T cells. There are several such strategies including expansion of tumor-
infiltrating lymphocytes (TILs) and retrovirus-encoded T cell receptors, but most 
commonly this is achieved by genetically modifying the patient’s own T cells to express 
a chimeric antigen receptor (CAR-T cells) [59]. The CAR itself often consists of the 
variable region of a monoclonal antibody to a tumor-expressed antigen which has been 
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grafted onto the internal signaling domains of the T cell receptor and, in newer iterations, 
other costimulatory molecules such as CD28 [60]. This strategy has proven quite 
effective against leukemia, but many solid tumors, including breast cancer, do not 
respond significantly to such therapies [61]. Some recent studies, however, have 
uncovered effective CAR-T targets, even on TNBC, and show promising results, 
including regression of primary tumors and lung metastases of human cancers implanted 
in immune deficient mice [62]. The promise of CAR-T cell therapy is not without its 
drawbacks. The most significant of these stems from the fact that the engineered T cells 
are highly effective at killing the tumor. In malignancies for which CAR-T cell therapy 
has been approved, especially if there is a high disease burden, such targeted cells can 
sometimes elicit the release of enormous amounts of pro-inflammatory cytokines, termed 
cytokine release syndrome (CRS). Release of large quantities of cytokines such as IFN-γ, 
IL-6, and GM-CSF can cause fever, shock, and liver failure. It is for this and other 
reasons that CAR-T cell therapy is often seen as a “double-edged sword”, and co-
administered inhibitors of some of these off-target effects may prove useful [63].   
Cancer vaccines move a step beyond checkpoint blockade in complexity of 
implementation, and hold promise as both adjuvant and long-term preventive therapies 
for patients with higher likelihoods of recurrence. The goal of these therapeutic vaccines 
is to sensitize the patient’s immune system to specific epitopes either unique to or 
enriched on the tumor cells, thus allowing the relatively specific targeting and destruction 
of the cancer by the patient’s own immune cells. Tumor cell destruction then releases 
additional cytokines and antigens that further boost and focus the immune response, 
which can be sustained long after treatment has ended [64]. This immunologic memory 
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allows the body to seek out and destroy the cancer systemically and stave off recurrence 
from disseminated micrometastases. The main challenges with this approach are to 
identify ideal tumor associated antigens (TAAs) which both are unique and produce an 
effective immune response. The identification of TAAs has been taking place since the 
late 1970s. The majority of these early endeavors were focused on mutations in what 
were then newly discovered cancer-causing genes and the aberrant proteins transcribed 
from them. Vaccines based on the proteins derived from oncogenes, and fusion proteins 
(such as BCR-ABL-1) were shown to be effective in mouse models and were tested 
clinically with mixed results. Proteins from oncogenic viruses such as human papilloma 
virus (HPV) and Epstein-Barr virus (EBV) have also been investigated. Patients with 
relevant virus-mediated cancers did possess limited numbers of T cells specific for viral 
proteins, but while results in mouse models were promising, none of these vaccines 
demonstrated clinical efficacy [65-67]. Since that time, more traditional preventive 
vaccines have decreased the incidence of several important oncogenic viruses and the 
malignancies often arising from chronic infection. Hepatitis B virus (HBV) vaccination 
efforts promise to prevent 1.5 million hepatocellular carcinoma (HCC) related deaths 
over the next 12 years, and human papilloma virus (HPV) vaccines have not only 
demonstrated drastic decreases in the incidence of both cervical and oral cancers, but 
have also resulted in the regression of extant neoplasia in some clinical trials (100% 
regression among some patient cohorts) [68-73]. Where these and other vaccines have 
previously only been tested as treatments, improvements in technology and a change in 
perspective have led to overwhelming success as preventative measures. There have also 
been efforts to use TAAs in the development of preventative vaccines for non-viral 
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mediated cancers in high risk patient populations. More recent efforts along these lines 
have been met with some success, especially with the TAAs MUC1 (here in ovarian 
cancer, though also implicated in some breast cancers) and HER2 [74]. This is likely 
because both of these antigens are required for the growth and development of their 
respective malignancies, and losing them to escape immune destruction would likely 
bring little selective advantage for the tumor.  
One problem with the early therapeutic vaccine efforts is the fact that the vast 
majority of tumor antigens to which there is an adaptive immune response are non-
mutated proteins which are overexpressed in tumors. The early focus was on peptide and 
peptide plus adjuvant designs, similar to preventative vaccines, but since 1990 
overexpressed TAAs have become the focus of vaccine design. Some of the first attempts 
at breast cancer vaccination were peptide vaccines using the familiar marker HER2, and 
at least one such HER2-peptide vaccine therapy, nelipepimut-S, is currently undergoing 
phase III clinical trials. Nelipepimut-S is a nine amino-acid peptide (E75) from the 
extracellular domain of HER2 [75]. Many patients with HER2-expressing breast cancer 
have been found to already have some level of immunity to E75 antigen, and in this 
subset of cancers, it has demonstrated clinical benefit [76].  
As the importance of dendritic cells (DCs) as professional antigen presenting cells 
became clear over this time period, and the techniques required to generate large 
quantities of autologous DCs were developed, these cells came to be viewed as the best 
vehicles for antigen delivery and initiation of a tumor-specific adaptive immune response. 
Hundreds of DC-based vaccine trials were carried out for many different cancers [77, 
78]. Viruses, virus-like particles, and bacterial vectors were also engineered to carry 
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tumor antigens as vaccines [75, 79, 80]. Emerging knowledge of the stimulatory effects 
of toll-like receptor (TLR) agonism on antigen presenting cells led to the inclusion of 
TLR ligands as adjuvants in vaccines to more robustly activate the immune system. In 
spite of all of these advances and refinements, most of these vaccines had little impact on 
disease-free survival, overall survival, or recurrence [81]. In order to shed light on the 
reasons for these shortcomings and guide future vaccine development, several meta-
analyses have been performed on hundreds of these trials. A key conclusion from these 
meta-analyses is that the vast majority of vaccines phase II trials did not demonstrate 
statistically significant benefit and never moved on to phase III (only 4% did). This likely 
may have been due to the limited duration of outcome monitoring, and none of the 
studies analyzed contained long term (>10 years) follow-up statistics. However, 12-year 
survival rates have recently been reported for an ex vivo matured autologous DC vaccine 
against non-resectable metastatic melanoma. 19% of these patients were alive after this 
lengthy period of time, an impressive result for an aggressive disease with a normally 
very poor prognosis. This result is comparable to treating similarly severe melanoma with 
FDA-approved CTLA4 checkpoint blockade therapy [82].  
Though no breast cancer vaccines are currently available, many either have been 
or are currently under development. The first, and only true, FDA-approved cancer 
vaccine, sipuleucel-T, was approved for the treatment of hormone-resistant metastatic 
prostate cancer in 2010, but no such vaccines have been approved thus far for any other 
malignancies [83]. Sipuleucel-T is a DC-based vaccine. Its implementation involves the 
extraction of the patient’s own circulating monocytes, which are then incubated with a 
fusion protein called PA2024 made up of granulocyte monocyte stimulating factor (GM-
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CSF) and prostatic acid phosphatase (PAP), an antigen present in almost all prostate 
cancer cells. This stimulates the differentiation of the immature monocytic cells into DCs 
as well as their maturation into effective presenters of the provided tumor antigen, PAP. 
These cells are then re-infused into the patient three times over a 6-week period [84]. To 
date, two phase III clinical trials have demonstrated a modest, but statistically significant 
increase in patient survival after sipuleucel-T treatment.  
Another possible reason for the failure of these vaccines could have been the fact 
that the participants in most of these trials were patients with advanced disease and, 
likely, significant immune suppression. Even mature DCs bearing potently immunogenic 
antigen were insufficient to overcome this environment and carry out the desired 
tumoricidal activity. To combat this, there are three obvious avenues by which better 
vaccine success rates may be achieved, all of which may in the end be combined for 
maximal effect. First, more complex vaccines containing many potentially effective 
tumor antigens and adjuvants may provide more robust immune stimulation than the 
single antigens tested in the majority of these trials. Second, enrolling patients with early 
stage disease might allow the introduction of vaccine material into a less immune-
suppressive micro-environment, where it stands a better chance of beneficially increasing 
the patient’s own antitumor immune response. Third, ex vivo genetic manipulations of 
autologous DCs may increase their capacity for maturation and decrease their 
vulnerability to intratumoral immunosuppression, again allowing the vaccine to better 
carry out its function as intended [85].   
Several more recent clinical trials of DC-based vaccines in patients with pre-
malignant breast lesions, ductal carcinoma in situ (DCIS), have demonstrated favorable 
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results. These have taken advantage of the effectively immunogenic TAA, HER2. One 
such trial used the following strategy. Four weekly autologous DC vaccinations were 
administered to 13 patients prior to surgery. These DCs, loaded with HLA class I-binding 
and HLA class II-binding HER2-derived peptides, were matured and activated in vitro. In 
order to maximize the immune response and ideally place the DCs for successful tumor-
primed T cell interaction, the vaccine was injection into regional lymph nodes likely to be 
draining the tumor bed. All patients developed HER2 peptide-specific CD4+ and CD8+ 
cells as well as a robust tumor-lytic antibody response. ~64% of patients were found to 
have a decreased DCIS burden at surgery and remaining DCIS contained a significant T 
and B cell infiltrate. Accompanying this decrease in tumor size, HER2 expression was 
also decreased, which also likely had a direct impact on tumor cell survival [86]. A 
second trial, in which 27 patients with DCIS participated, replicated these favorable 
results. After following the same vaccination schedule, five of the 27 patients were found 
to have no evidence of DCIS at surgery. Half of the remaining 22 patients had lost their 
HER2 expression [87]. Thus far, there has not been follow-up or disease outcome data 
collected for these studies, but as the prognosis for DCIS is usually quite good, a high 
long-term survival rate and low incidence of recurrence would be expected even without 
this increased tumoricidal immune response.  
During the early period of cancer therapeutic vaccine development, the induction 
of systemic immune suppression by the tumor was largely unknown, but since that time, 
many mechanisms of immune suppression have been discovered and provide potential 
immune therapeutic targets. It is very likely that groups of these strategies will be shown 
to function well together, and just as tumor cells take advantage of many mechanisms to 
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compromise host immunity, treatments will need to counteract these efforts on multiple 
fronts simultaneously. Some of the primary immune suppressive cell populations that 
have been targeted are monocyte-derived suppressor cells (MDSCs) and tumor associated 
macrophages (TAMs). Multiple aspects of these cells have become the focus of proposed 
therapeutic perturbations whether through blocking growth factor receptors such as CSF-
1 [88], altering metabolic pathways such as fatty acid oxidation or glycolysis [89], or 
blocking the activity of certain key enzymes such as indoleamine 2,3-dioxygenase 1 
(IDO1) [2, 90-92]. Combinations of these innate immune therapies, checkpoint 
inhibition, T cell transfer, and therapeutic vaccines may have the most significant and 
universal antitumor effects [93]. The relative successes of checkpoint inhibition and 
CAR-T cells, coupled with new data supporting the inclusion of therapeutic vaccines as 
part of combination immunotherapy, has led to a significant recent increase in enthusiasm 
for therapeutic vaccine development as a part of a multi-pronged approach.  
As the breast cancer molecular subtype with the most limited number of treatment 
options, TNBC is often the focus of new combination immunotherapeutic approaches. 
The only completed clinical trial to date testing the efficacy of immune checkpoint 
inhibitors on TNBC, specifically, demonstrated a benefit to only a limited number of 
patients [94]. Oncolytic virotherapy has been found to enhance general antitumor 
immunity, reduce forced recurrence, and render TNBC more vulnerable to checkpoint 
blockade in murine studies [95, 96]. Studies into TNBC genomic data has yielded a 
surprising, and fortuitous finding. Almost all of the immune activation pathways were 
enriched to a significantly higher degree in TNBC versus non-TNBC [97]. This means 
that it may be the case that while TNBC expresses no traditionally targeted antigens, it is 
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the most immunogenic molecular subtype and may be the most vulnerable to immune 
therapy. The majority of immune checkpoint genes, including CTLA4 and PD-1, are 
overexpressed in TNBC compared to non-TNBC and normal tissue. There is also a much 
higher density of tumor-infiltrating lymphocytes in TNBC than non-TNBC, though it is 
important to remember that many of these cells are immune suppressive and would be 
negative prognostic indicators. However, it was found that CD57 expression was more 
abundant in TNBC than in non-TNBC; CD57 is a marker of activated T and NK cells. 
Other proinflammatory genes such as IFNγ and IRF1 are also enriched in triple negative 
tumors [97]. Overall the genomic profiling of these tumor samples paints a picture of 
TNBC as both a highly immunogenic and highly metastatic tumor which may prove a 
fruitful target for checkpoint inhibition, therapeutic vaccination, and various combination 
immunotherapies.   
The future success of cancer immunotherapy will depend on the rapid 
identification and/or use of novel immunogenic antigens. Delivery of these antigens by 
the optimal vehicle, such as DCs, viruses, or some other yet to be discovered mechanisms 
will also be key to future therapeutic success. Coupling these therapies with adjuvants 
and immune modulatory treatments such as checkpoint blockade, IDO1 inhibition, or 
other innate immune therapies will allow for the more comprehensive targeting of the 
breast cancer immune regulatory network and improved therapeutic success. In the 
experiments described here, the development of two immune therapeutic modalities and 
strategies are discussed. Each is intended to both bring basic murine models of 
experimentation closer to the patterns of clinical application and to further the 
development of two immune therapies toward use in human patients. The first of these 
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therapies is emodin, a natural compound derived from several herbs used in traditional 
Chinese medicine (TCM) [98]. It has been shown to have numerous immune modulatory 
properties [99-102], but our lab was the first to demonstrate its ability to attenuate breast 
tumor progression through its effect on macrophage-cancer cell interaction [103]. Here 
emodin is tested in a murine model of tumor resection as an adjuvant therapy to prevent 
metastatic recurrence of triple negative breast cancer. Its proven low toxicity and ability 
to disrupt the reciprocal signaling between tumor cells and macrophages make it a 
promising innate immunotherapy [104]. The second therapeutic strategy involves genetic 
modification of DCs to increase their immune stimulatory capabilities and the 
implementation of these modified DCs as therapeutic breast cancer vaccine. Our lab was 
again the first to reveal the role of microRNA-155 (miR155) as a key regulator of DC 
function and mobility [105]. We have previously demonstrated that total-body knockout 
of miR155 increased both tumor growth and metastasis in an orthotopic model of murine 
breast cancer; here total immune system overexpression of miR155 and a miR155-
overexpressed DC vaccination therapy are shown to suppress murine breast tumor 
progression. Some of the relevant parameters of DC maturation, migration to draining 
lymph nodes, and activation of T cells are also investigated using these miR155-






GENERATION OF A MOUSE MODEL FOR TRIPLE-NEGATIVE BREAST 
CANCER POST-SURGERY METASTATIC RECURRENCE 
2.1 BACKGROUND 
Historically, the drug development process for cancer therapeutics has relied 
heavily on preclinical murine models to determine the effectiveness of treatments in vivo. 
Especially in the case of using immune deficient mice bearing human cancer cell lines or 
explants, these models have had difficulty in predicting treatment efficacy for patients 
[106, 107]. The tumor microenvironment in a largely immune competent human is often 
found to respond very differently to treatments leading to many failed clinical trials [108, 
109]. In order for mouse models to be more predictive of clinical success, whenever 
possible it is advantageous to use immune competent mice. The interplays between tumor 
cells, immune cells, and other stromal cell populations determine the efficacy of therapies 
in patients where these interactions also shape disease progression. This is particularly 
true when testing targeted therapies and immunotherapies [108, 109]. It is also very 
common for studies to not focus on the most appropriate measures of therapeutic success 
or endpoints. Many murine studies of cancer progression focus on inhibiting tumor 
growth and monitor it as the key phenotypic finding, with a reduction in final tumor 
weight indicating positive therapeutic benefit. While reduction in tumor size is a 
welcome clinical outcome, it is usually only a minor component of overall therapeutic 
goals related to easing surgical excision or a step toward eradication of a highly 
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invasive/disseminated malignancy (which has a relatively low success rate). 
Overemphasizing primary tumor growth retardation can sometimes lead to the use of 
therapies that simultaneously encourage metastatic spread and local recurrence. This is 
the case with some systemic cytotoxic therapies, and has been largely attributed to the 
induction of a pro-tumor immune response to the dying tumor cells [110-113]. Clinical 
outcomes are usually measured in terms of progression-free survival and overall survival, 
criteria that often largely depend on the degree of tumor metastatic progression after 
treatment [114]. Preclinical, immune-competent murine models mirroring the treatment 
strategies and schedules actually used to treat human breast cancer should serve as a 
better predictor of patient outcomes when/if therapies progress to clinical testing [115].  
In an attempt to do just this, we have established a murine model of highly 
metastatic TNBC, which as closely as possible, seeks to imitate the progression from of 
diagnosis to surgical excision and subsequent adjuvant therapy to prevent metastatic 
recurrence experienced by breast cancer patients [116]. Non-invasive molecular imaging 
was used to estimate the extent of metastatic dissemination leading up to and after 
surgical resection. As the eventual purpose of the model is to test the effect of emodin 
treatment on metastatic recurrence, the optimal traceable cell line, injection site, and 
time-point for tumor resection have to be determined where metastases would eventually 
arise in untreated mice but are not detectable at the time of surgery. This recurrence could 
be the result of existing micrometastases or circulating tumor cells present at the time of 
tumor removal, but exhaustive studies to parse this out have not been performed. At this 




2.2 PRELIMINARY TEST OF METASTATIC RECURRENCE MODEL 
2.2.1 DETAILED MEHTODS 
Tumor models 
7 week-old, female BALB/c mice were purchased from Jackson Labs (Bar 
Harbor, ME), and were housed at the University of South Carolina Animal Research 
Facility for one week prior to experiments. All procedures were approved by the 
University of South Carolina Institutional Animal Care and Use Committee. 4T1-luc2-
RFP cells were generated by transducing 4T1-luc2 cells (PerkinElmer, Waltham, MA) 
with pWPI-RFP lentivirus. The resulting 4T1-luc2-RFP cells were sorted using a FACS 
Aria II (BD Biosciences, San Jose California) and stored in liquid nitrogen. 4T1-luc2-
RFP cells were recovered from liquid nitrogen storage and passaged not more than three 
times to expand before inoculating BALB/c mice. 4T1-luc2-RFP cells were washed twice 
in PBS after harvesting with 0.05% Trypsin/EDTA and resuspended in PBS at a density 
of 10x106 cells/mL. On Day 0, 30 8-week-old female Balb/c mice were bilaterally 
injected with 2x105 4T1-luc2-RFP tumor cells in the 4th pair of mammary fat pads by 
creating a 1 mm-long incision about 1 mm inferior to the nipple and using a short, 
beveled needle for cell implantation. This blunt needle method was used to help ensure 
delivery of the tumor cells into the fat pad tissue at a shallow depth without entering the 
peritoneum. On Day 6, mice were separated into 3 groups based on equal average tumor 
volume. On Day 8, hair was removed from the surgical field using a depilatory cream in 
preparation for surgery. Tumors were allowed to grow for 10 days to a volume of ~200 
mm3 before removal. Tumor volume was calculated using the following formula: (short 
axis)2 x (long axis)/2 ≈ volume. The tumors were removed on Day 10. On Day 11, the 
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three groups of mice received i.p. injections of PBS with 2% DMSO by volume 
containing either 0 mg/kg, 20 mg/kg or 40 mg/kg emodin. The volume of these injections 
was ~800 µL per mouse. These i.p. injections were administered daily for the next two 
weeks. After two weeks of daily injections, injections were given every other day for two 
more weeks. When mice died during the course of this study or exhibited significant 
moribundity and were sacrificed, their lungs and other metastatic sites identified on IVIS 
Spectrum (PerkinElmer) imaging were taken for counting of metastatic 
nodules/determination of metastatic burden. On Day 42 the lungs of surviving mice were 
removed for metastatic and immune cell population analyses.  
Tumor removal procedure  
Each mouse was anesthetized using an isoflurane vaporizer and maintained under 
anesthesia for the duration of the surgery with the vaporizer set to deliver 2% isoflurane. 
The surgical field was cleaned liberally with 70% ethanol and betadine swabs. A 1-2 cm 
incision was made medial to the tumor, and the tumor, with as much surrounding fat pad 
as possible, was resected. An electrocautery unit was on hand to stop excess bleeding if 
necessary. Incisions were closed with stainless steel clips and suture. Mice were allowed 
to recover in a cage heated to 30˚C. 
IVIS Imaging 
BALB/c mice bearing 4T1-luc2-RFP tumors were imaged using an IVIS 
Spectrum (PerkinElmer). Prior to data collection, a kinetic curve was collected. To do 
this, D-luciferin (Sigma-Aldrich Corp., St. Louis, MO) was dissolved in PBS at a 
concentration of 15 mg/mL. Mice received 10 µL of this solution per gram body weight 
intraperitoneally (i.p.), were anesthetized using an isoflurane vaporizer, and imaged at 
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600 nm wavelength beginning 10 min after having received the D-luciferin injection. 
Images were obtained once per minute for the next 30 min while the mice were 
maintained under anesthesia at 1.5% isoflurane. Metastatic recurrence was monitored 
using the IVIS Spectrum to image the luciferase activity in the 4T1-luc2-RFP cells using 
the same imaging procedure described for kinetic curve determination, but only one 
image was collected at 10 min. IVIS imaging began on Day 13 and continued weekly 
until the termination of the experiment.  
Flow Cytometry 
Lung tissue was collected from the surviving mice on Day 42, cut into small 
fragments and digested using the following mixture of enzymes in serum-free RPMI at 
37˚C for 45 min: 10 mg collagenase IV (Worthington Biochemical Corp., Lakewood, 
NJ), 10 µg hyaluronidase (Sigma-Aldrich Corp.), and 100 µg DNAse I (Sigma-Aldrich 
Corp.). Red blood cells were then lysed in 3 mL RBC lysing Buffer (Sigma-Aldrich 
Corp.) for 5 min at RT. 25 mL PBS was added and each sample pelleted by 
centrifugation at 325 x g for 5 min. Cell pellets were resuspended in 10 mL PBS, passed 
through a 70-µm cell strainer, and pelleted by centrifugation. Cells were counted and 
1x106 cells from each sample was resuspended in 100 µL staining buffer (PBS 2% FBS). 
Cells were blocked with Fc blocking antibody (Biolegend, San Diego, CA) for 10 min at 
4˚C, then cells were stained with anti-CD3 FITC, anti-CD8 APC, anti-F4/80 FITC, and 
anti-CD206 APC (Biolegend) for 30 min at 4˚C. Cells were then washed twice with PBS 
and resuspended in 500 µL PBS for flow cytometry using a BD FACS Aria II and FACS 





Data were shown as mean ± standard error of mean (SEM) whenever the mean 
was the primary value representative of a sample group’s behavior. Two group 
comparison of means was accomplished using a 2-tailed Student’s t test. All such 
comparisons were performed using GraphPad Prism 5 software (Graphpad Software Inc., 
San Diego, CA). Differences between proportions were determined using a two tailed N-
1 Chi-Square test. Three group comparison of means was accomplished using a two 
tailed ANOVA followed by Tukey multiple comparisons test p≤0.05 was considered 
statistically significant for all tests.   
2.2.2 RESULTS 
The goals of this preliminary study were to (1) determine whether 10 days post-
orthotopic 4T1-luc2-RFP cell inoculation is a good time-point for tumor removal that 
ensures appropriate metastatic recurrence rate; (2) test the general metastatic potential of 
the 4T1-luc2-RFP cells and their tropism for lung tissue; (3) assess the survivability of 
our surgical technique; (4) determine the timescale for metastatic recurrence; and (5) 
determine whether emodin has an effect on metastatic recurrence. How well this model 
met or shed light on each of these objectives will be discussed as well as the future 
studies needed to fine-tune the method.  
10 days of tumor growth was insufficient to achieve an appropriately high metastatic rate 
with 4T1-luc2-RFP cells 
There were no statistically significant differences between average tumor volume 
or radiance between the groups prior to tumor resection as intended (Figure 2.1B&C). 
Three days after tumor resection, and after only three treatments, two mice in the 0 mg/kg 
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emodin group had obvious lung metastasis, and one of the mice in the 40 mg/kg emodin 
group exhibited signs of local recurrence or residual tumor (Figure 2.1D). We intended 
the surgery to completely eliminate the primary tumor, so this early local recurrence, 
likely due to incomplete removal, was not ideal, but others have experienced significant 
local recurrence when using a similar model [115]. The metastatic efficiency, or total 
percentage of mice in each group that developed metastasis, was 40% for the control-
treated group and 20% for both the 20 mg/kg and 40 mg/kg emodin-treated groups, 
meaning in total only 26.6% of the mice developed metastases in any part of their bodies 
(Figure 2.1E&F). Due to this very low metastatic efficiency across all groups, no 
statistically significant differences could be determined.  
Metastases did not occur preferentially in the lungs 
From our IVIS imaging, in addition to very few of the mice ever developing 
metastases, the majority of these metastases did not occur in the lung tissue. The majority 
of highly bioluminescent regions that were obviously not local recurrence seemed to be 
located in the jaw and shoulder areas of the mice (Figure 2.2A&2.1E). It was not 
possible to determine whether these growths originated in lymph node or bone upon 
necropsy or autopsy. Also what appeared on IVIS to be local recurrence on IVIS were 
found at sacrifice to largely be metastases to the inguinal and hind limb region (Figure 
2.2A&2.1E). Metastases occurred unpredictably with 4T1-luc2-RFP cells; other cell lines 
with more reliable lung tropism may be better for our purpose. Allowing tumors to grow 





Mice were able to recover from surgery and metastases appeared quickly 
None of the mice died as a direct result of the surgery in spite of the fact that two 
of the mice did remove their wound clips during the recovery period immediately 
following surgery and required re-suturing of their incisions. Also, all of the mice in 
which metastases did arise developed these by two weeks post-surgery (Figure 2.3A). 
This two week timeframe (~3 weeks since tumor implantation) is consistent with other 
studies tracking the progression of 4T1 tumors [117].   
Emodin treatment showed a decreasing trend in metastatic burden and an increasing 
trend in overall survival  
Our previous studies have shown that emodin not only reduces metastases when 
administered shortly after tumor cell implantation but also when tumors are already 
established [103, 118]. Here, though our metastatic efficiency is low and not specific to a 
single location after the orthotopic tumors were removed, we show that emodin treatment 
does appear to exhibit some trends toward decreasing metastatic recurrence after surgical 
resection of the primary tumor and increasing overall survival. The observation of this 
trend in this particular study is obscured by the fact that the only mouse that developed 
what appeared to be local recurrence was in the 40 mg/kg (high dose) emodin group 
(Figure 2.1E). This is most likely due to lack of experience performing the surgery and 
not due to the treatment itself. In this high dose emodin group, this mouse was the only 
one that developed lung metastases and may never have developed these had the primary 
tumor been completely removed. When only chest radiance is considered as a measure of 
metastatic burden, the high dose emodin group had the lowest overall metastatic burden 
by a large margin, and the low dose emodin group fell between the control and high dose 
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emodin groups in chest radiance until mice began to die due to the progression of their 
disease (Figure 2.4A). Metastasis-free survival also exhibited a trend toward emodin 
reducing metastatic recurrence, though it did not reach statistical significance (Figure 
2.4B). Overall survival paralleled metastasis-free survival, but the low mortality rates and 
small sample sizes yielded insufficient statistical power for differences to manifest 
(Figure 2.4C). The surviving mice at the conclusion of the study were not bearing any 
lung metastases (Figure 2.4D); nonetheless flow cytometric analysis was performed of 
lung macrophages and CD8+ T cells. There was unsurprisingly no difference in the total 
T cell burden in the lungs and only a slight, statistically insignificant increase in CD8 
positivity among the mice receiving emodin treatment (Figure 2.4E). The F4/80 staining 
yielded no positive cells, which further study revealed was due to excessively harsh 
enzymatic digestion destroying the F4/80 expressed on the surface of the lung 
macrophages.  
2.2.3 DISCUSSION 
The data from this experiment show that many of our objectives for this model 
were not met, but do point toward ways of improving these deficiencies. First and most 
importantly, 10 days of tumor growth prior to resection was not adequate to induce 
enough metastases to be able to study the potential impact of therapies on metastatic 
recurrence with reasonable sample size. Future studies will monitor lung fields with IVIS 
imaging more frequently in order to attempt to gage when metastases begin to be visible. 
Then a study similar to this one will be repeated with tumors being removed a few days 
prior to this determined time of macro-metastasis establishment.  
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This particular strain of 4T1-luc2-RFP cell also does not appear to have a highly 
specific lung tropism in this fat pad injection followed by surgical resection model. The 
original purpose of using this cell line was to (1) have a highly aggressive model of 
TNBC, (2) be able to take advantage of the non-invasive molecular imaging afforded by 
the luciferin to monitor metastatic recurrence, and (3) to be able to analyze the level of 
red fluorescent protein (RFP) expression in a single cell suspension of lung tissue to 
easily determine metastatic burden. For the purposes of this study, the least important of 
these objectives is the presence of RFP to measure metastatic burden. This can be 
determined by counting and quantifying metastatic area on serial sections taken at 
measured intervals and stained with hematoxylin and eosin (H&E). It may be possible to 
perform a metastatic kinetics study using 4T1-luc2 cells without the RFP in order to see 
if these cells metastasize more predictably while still be monitored in vivo using the IVIS 
Spectrum.  
The surgical method seems adequate for yielding high survivability and relatively 
low local recurrence. In future experiments a little more normal tissue around the tumor 
will be taken in order to ensure clean margins, and it remains to be seen how feasible this 
will be if tumors are allowed to grow larger to ensure a higher percentage of metastasis-
bearing mice. It may be more difficult to effectively close the larger incisions.  
With macrometastases appearing within one to two weeks after surgical resection, 
this timetable is quicker than expected, but adequate to administer several doses of 
treatment before the development of overt metastases. It remains to be seen if allowing 
the tumors to grow longer will affect the rate of metastatic spread. It is possible that the 
trauma of surgical resection itself may aid in metastasis, so once again improvement of 
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surgical technique may improve the overall outcome of studies using this tumor resection 
model.  
Due to the deficits in the model, it is not possible to definitively determine 
whether or not emodin treatment affected metastatic recurrence. Once further studies are 
performed to improve this model, it may be possible to observe more definitive results in 
metastatic burden, progression-free survival, overall survival, and immune cell infiltrate 
at the metastatic site due to adjuvant therapy with emodin.  
2.3 4T1-LUC2-RFP METASTASIS TIME-POINT AND TROPISM 
2.3.1 DETAILED METHODS 
Tumor Model 
BALB/c mice were housed at the University of South Carolina Animal Research 
facility until 8 weeks of age for use in this experiment. All procedures were approved by 
the University of South Carolina Institutional Animal Care and Use Committee. Tumor 
cell implantation was performed as described previously. Briefly, 4T1-luc2-RFP cells 
(PerkinElmer) were resuspended in PBS at a density of 10x106 cells/mL. On Day 0, 15 
female Balb/c mice were bilaterally injected with 2x105 4T1-luc2-RFP tumor cells in the 
4th pair of mammary fat pads. Tumor volume was calculated as stated before and was 
measured every 3 days beginning at Day 11. Mice were divided into three groups of five 
mice each with equal average tumor volume on the day that tumors were to be removed 
from the first group of mice. This first resection took place, as described previously, 
when the average volume reached 500 mm3. Tumors were removed from the second 
group at 1000 mm3 average volume and the third group at 1500 mm3 average volume. 
These volumes were reached on Days 18, 22, and 26, respectively, since tumor cell 
implantation. Mice were imaged using the IVIS Spectrum (PerkinElmer) prior to tumor 
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removal and weekly thereafter until the conclusion of the study. When mice died during 
the course of this study or exhibited significant moribundity and were sacrificed, their 
lungs and other metastatic sites identified on IVIS Spectrum imaging were taken for 
gross determination of metastatic burden. On Day 52 the lungs of surviving mice were 
removed for gross determination of metastatic burden.  
IVIS Imaging 
BALB/c mice bearing 4T1-luc2-RFP tumors were imaged using the IVIS 
Spectrum (PerkinElmer) prior to tumor removal, and each cohort of mice was imaged 
after tumors were resected in order to gage the completeness of resection and presence of 
metastasis at the time of tumor removal. Mice were then imaged weekly thereafter. Mice 
were allowed to recover for 10 min in order for the D-luciferin to fully perfuse the mouse 
and were then re-anesthetized and imaged at 600nm wavelength. Photons/second was 
used to determine the luminous flux from the tumor cells and adjust for differences in 
exposure time.  
Statistical Analysis 
Data were shown as mean ± standard error of mean (SEM) whenever the mean 
was the primary value representative of a sample group’s behavior. Three group 
comparison of means was accomplished using a two tailed ANOVA followed by Tukey 
multiple comparisons test, while two group comparison was accomplished using a two 
tailed Student’s t test. All such comparisons were performed using GraphPad Prism 5 
software (Graphpad Software Inc.). Differences between proportions were determined 
using a two tailed N-1 Chi-Square test. p≤0.05 was considered statistically significant for 




This study was performed to determine the amount of time required between 4T1-
luc2-RFP cell inoculation and tumor resection in order to achieve ≥80% metastatic 
recurrence rate under control/untreated conditions. The secondary purpose of this study 
was to again observe the metastatic tropism of the 4T1-luc2-RFP cells and determine 
whether lung metastasis alone could be used as a measure of metastatic recurrence. If the 
metastatic pattern is too erratic, then quantification of total body metastases and 
observation of the effect any treatment may have on this would be much more difficult. 
Our previous study had shown that 10 days of tumor growth, producing a 200 mm3 tumor 
prior to resection, was too little time for the tumor to metastasize in a majority of the 
mice, and many of the metastases that did occur formed outside of the lungs.  
The metastatic tropism of 4T1-luc2-RFP cells following primary tumor resection is not 
lung-specific 
 The average tumor volume of all tumor-bearing groups was the same at the time 
of each tumor surgery, when multiple groups were still bearing tumors, as intended 
(Figure 2.5B). The average tumor radiances were also the same at each of these time-
points (Figure 2.5C). The increasing average tumor weights at each of the sequential 
resections mirrors the increasing volume measurements, and proves to be a much less 
variable indicator of tumor size than the radiance data collected from the IVIS Spectrum 
(Figure 2.5D).  
Upon tumor resection, mice in each group were imaged using an IVIS Spectrum 
to determine whether or not the entire tumor had been resected and the locations of any 
pre-surgical metastases. After the first group of tumors had been removed on Day 18 
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(Group 1), one of the mice presented with residual local tumor tissue upon Day 19 IVIS 
imaging (Figure 2.5E). After the second resection on Day 22 (Group 2), one of the mice 
in Group 1 seemed to exhibit an established lung metastasis, but none of the Group 2 
mice appeared to have any residual tumor or metastases on Day 23 IVIS imaging (Figure 
2.5E). Upon resection of the third group of tumors (Group 3) on Day 26, three out of the 
five mice were found to already possess distant metastases, two of which were in the lung 
fields on Day 27 IVIS imaging (Figure 2.5E). The third was located in the shoulder/jaw 
region as observed previously when testing this model. One of these lung metastasis-
bearing mice also presented with substantial residual tumor tissue at one of its excision 
sites. One of the mice in Group 2 presented with a non-lung distant metastasis, and three 
mice in Group 1 appeared to exhibit some rapidly growing local recurrence. One of these 
mice also still seemed to show the previously noted lung metastasis (Figure 2.5E). 
Before the next IVIS Spectrum imaging on Day 38 post tumor implantation, two mice in 
Group 3 died, necropsy showed that these deaths were likely due to metastatic spread of 
the tumor. One of these mice had significant residual tumor and lung metastases obvious 
on IVIS Spectrum imaging, while the other was found to have some relatively small lung 
metastases on necropsy as well as a substantial tumor in the jaw/neck region (Figure 
2.5E). Day 45 IVIS Spectrum imaging revealed that of the five mice in Group 1, one 
appeared to still have a relatively stagnant local recurrence, while another of the mice 
exhibited bilateral local recurrence and lung and other metastases. One of the mice in 
Group 2 showed a potential local recurrence and a large shoulder metastasis. Of the three 




Gross lung metastases only developed after 26 days of tumor growth before resection 
The final IVIS Spectrum imaging was done on Day 52 since tumor cell 
implantation. On this date, another mouse in Group 3 died, and though it was not 
apparent that lung metastases were present in previous images, many large metastases 
were present on necropsy (Figure 2.6A). Another mouse in Group 3 that had exhibited a 
lung metastasis for the past several weeks was also moribund and would have required 
sacrifice even if this had not been the final day of the experiment. Two of the mice in 
Group 1 were sacrificed due to impairment brought on by their metastases prior to Day 
52 imaging, both exhibited what appeared to be metastases upon necropsy, yet none were 
present on the lungs. All of the metastases visualized on IVIS Spectrum imaging of 
Group 1 mice were located, and even those appearing to be in the region of the lung 
fields were either outside of or originating from the ribcage. Mouse #1 in this group 
appeared to have a local recurrence from IVIS Spectrum imaging, but necropsy showed 
that this was found to be associated with the muscle/bone of the hind limb, and did not 
appear to originate from the primary tumor site. All of the mice in Group 2 survived until 
termination of the experiment, though two appeared to bear tumor cells in various 
locations on IVIS spectrum imaging. Interestingly, when all of mice were sacrificed, it 
was found that none of the surviving mice from Group 2 had any lung metastases, and 
only one metastasis was present on the lungs of one of the Group 1 mice, yet all three of 
the Group 3 mice examined did exhibit lung metastases (Figures 2.6A&B). Thus, there 
were only 3 mice in Group 1, 5 mice in Group 2, and 3 mice in Group 3 that survived 





 The results of this study were at times difficult to interpret during its course, and 
the most important finding was only apparent once all mice had been sacrificed. Only the 
26-day tumor resection time-point yielded ≥80% lung metastases. Only a single 
metastatic nodule was observed on the lungs of mice with tumors removed at either of the 
earlier time-points. This was the case even with the single instance of local recurrence in 
Group 1, which still exhibited no lung metastases. These findings indicate both that the 
tumors must be allowed to grow for a great deal more time that originally suspected in 
order to reliably (≥80%) yield lung metastases and that the 4T1-luc2-RFP cell line 
continues to produce a substantial proportion of extra-pulmonary distant metastases. 
Allowing the tumors to grow to the substantial volume of 1500 mm3 made clean resection 
much more difficult and caused there to be less skin available to properly close the 
incisions from which the tumors had been removed.  
  Both of these findings pose their own problems and the following potential 
solutions are proposed. First, to attempt to solve the difficulties in resecting such large 
tumors, only a single tumor injection into the right, 4th (9th) mammary fat pad will be 
performed in subsequent studies. This should allow enough tissue to remain to effectively 
close the excision site even if more tissue is taken to leave clean margins on a larger 
tumor. Second, to attempt to both shorten the time to micrometastasis establishment and 
identify a tumor cell line with more specific lung metastatic tropism, 4T1-luc2 cells will 
be used. Studies comparing these two cell lines and others expressing one or multiple 
tagging proteins have shown that adding more of these “useless” proteins can adversely 
affect tumor progression and ever serve as immunogenic antigens [119]. We have also 
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shown that not all of the 4T1-luc2-RFP cells express high enough levels of RFP to 
distinguish them from the native tissue, and thus it is unlikely that they can fulfill their 
originally intended purpose as an easy target to determine lung metastatic burden. 
Additionally, other more widely accepted measures of metastatic burden are not difficult 
to perform in future studies. Thus, future studies will be performed to test the usefulness 
of a unilateral 4T1-luc2 tumor cell implantation followed by a 20+ day tumor progression 
period followed by resection model as a method of reliable induction of lung metastases 
with a micrometastatic/circulating tumor cell treatment window.  
2.4 9th MAMMARY FAT PAD 4T1-LUC2 METASTASIS MODEL 
2.4.1 DETAILED METHODS 
Tumor Model 
8-12-week-old female BALB/c mice were injected with 2x105 4T1-luc2 cells 
suspended in 20 µL PBS into only the right, 4th (9th) mammary fat pads. The target tumor 
size for metastasis determined in the previous study was 1500 mm3. Tumors were 
measured every 3 days beginning at Day 10 until they reached this size. Once the target 
tumor volume was reached (Day 28), IVIS images were obtained and mice were 
separated into two groups based on equal average tumor size and metastatic burden while 
also maintaining equal average ages between groups. Tumors were resected on Day 28 as 
described previously, and i.p. injections of PBS, 2% DMSO by volume containing either 
0 mg/kg or 40 mg/kg emodin were administered daily beginning on Day 29. Volume of 
injection was calculated based on mouse weight, and ranged from 0.8 mL to 1 mL. 
Injections were given until mice died or were sacrificed due to moribunity. Survival 
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proportions were tracked until the last mouse was sacrificed (Day 41 since tumor 
injection).   
IVIS Imaging 
BALB/c mice bearing 4T1-luc2 tumors were imaged using the IVIS Spectrum 
(PerkinElmer) as described previously in Subsection 2.3 prior to tumor removal, and all 
mice were imaged after tumors were resected, to gage the completeness of resection and 
presence of metastasis at the time of tumor removal. Photons/second was used to 
determine the luminous flux from the tumor cells and adjust for differences in exposure 
time.  
Statistical Analysis 
Data were shown as mean ± standard error of mean (SEM) whenever the mean 
was the primary value representative of a sample group’s behavior. Two group 
comparison was accomplished using a two tailed Student’s t test. All such comparisons 
were performed using GraphPad Prism 5 software (Graphpad Software Inc., San Diego, 
CA). Survival data were analyzed using the Mantel-Cox log-rank test. p≤0.05 was 
considered statistically significant for all tests.  
2.4.2 RESULTS 
4T1-luc2 cells metastasize almost exclusively to the lungs 
 The 4T1-luc2 cells, surprisingly, took two days longer to reach the target volume 
for removal (1500 mm3) than the 4T1-luc2-RFP cells did. However, the 4T1-luc2 cells 
exhibited earlier metastatic dissemination. ~64% of the mice were found to have overt 
lung metastases on IVIS Spectrum imaging 24 h after primary tumor removal, and these 
metastases were visible prior to tumor excision when the primary tumor was covered 
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during imaging to prevent the much brighter tumor tissue from saturating the detector 
(Figure 2.7B).  
Emodin increased overall survival in lung metastasis bearing mice 
 Mice were divided evenly between 40 mg/kg emodin treatment and vehicle 
control groups based on tumor volume/radiance and lung field radiance, indicative of 
metastatic dissemination prior to tumor resection (Figure 2.8A). There was also no 
difference between lung field radiance 48 h after primary tumor removal (Figure 2.8B). 
Several of the mice also appeared to have residual primary tumor tissue after surgery. 
Emodin and vehicle i.p. injections were given daily until the conclusion of the study, 
which was only 13 days after tumor resection. The health of the mice deteriorated much 
more rapidly than in previous studies due the presence of advanced disease at the time 
treatment was initiated. We found that even this abbreviated course of emodin treatment 
led to a statistically significant increase in the median overall survival of the mice by 
19% (Figure 2.8C). Additionally, the final 3 emodin-treated mice were sacrificed once 
statistical significance was reached due to the fact that they were exhibiting some signs of 
labored breathing due to the presence of lung metastases. It is likely, however, that these 
mice may have survived a few more days before they each died or became impaired to 
the extent requiring sacrifice. All of the mice in both groups were found to have extensive 
lung metastasis on necropsy or at sacrifice. This was likely due to their being established 
prior to tumor resection and adjuvant therapy.  
2.4.3 DISCUSSION 
 This experiment demonstrated that the 4T1-luc2 cells implanted only into the 9th 
mammary fat pad had a more rapid onset of metastasis and exhibited a much more 
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specific lung tropism than the 4T1-luc2-RFP cells implanted bilaterally. It is not clear 
from this study whether this improvement is due solely to the change in cell line or in 
injection location or is affected by both, and knowing this is not crucial for the design of 
our final study.  
In this study, the 4T1-luc2 cells had already established observable metastases in 
a majority of the mice before tumor removal, and several of the mice bore residual tumor 
tissue post-surgery. Our goal is to apply emodin treatment to mice bearing only 
micrometastases and circulating tumor cells with no local recurrence and no lung 
metastases visible on post resection IVIS Spectrum imaging. In order to accomplish this, 
mice will be imaged frequently during the course of tumor growth with the tumors 
obscured. This should allow for the observation of the first detectable lung metastases 
and initiation of emodin treatment when the majority of the mice have either only very 
small metastases or circulating tumor cells. More tissue will also be removed around the 
primary tumor to ensure clean margins.  
We also found that even mortality due to the progression of established lung 
metastases can be delayed by emodin treatment at a dose that we have used previously 
and have shown to not be directly tumoricidal [103, 118].   
2.5 FINAL 4T1-LUC2 METASTATIC RECURRENCE MODEL TEST 
2.5.1 DETAILED METHODS 
Tumor Model 
27 7-week-old, female BALB/c mice were purchased from Jackson Labs, and 
were housed at the University of South Carolina Animal Research facility for one week 
prior to use in experiments. At 8 weeks of age, all mice were injected with 2x105 4T1-
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luc2 cells (PerkinElmer) suspended in 20 µL PBS into only the 9th mammary fat pad. The 
target date for tumor resection was between 20 and 25 days after tumor cell implantation. 
Tumors were measured every 3 days beginning at Day 11. Mice were separated into three 
groups based on equal average tumor volume measured on the day of tumor resection. 
Tumors were resected on Day 23 as described previously, and i.p. injections of PBS, 2% 
DMSO by volume containing either 0 mg/kg, 20 mg/kg, or 40 mg/kg emodin were 
administered daily beginning on Day 24. Injection volume was calculated based on 
mouse weight, and ranged from 0.8 mL to 1 mL. Injections were given daily until the 
termination of the study. Three mice from each group with obvious lung metastases one 
week after surgery were sacrificed. The remaining mice were sacrificed at 2 weeks post 
tumor resection.  
IVIS Imaging 
BALB/c mice bearing 4T1-luc2 tumors were full-body imaged using the IVIS 
Spectrum (PerkinElmer) prior to, 48 h after, and one week after tumor resection as 
described in Subsection 2.3. Photons/second was used to determine the luminous flux 
from the tumor cells and adjust for differences in exposure time.  
The lungs of mice were also imaged ex vivo using the IVIS Spectrum. To do this, 
two more solutions of D-luciferin were prepared at 150 µg/mL and 300 µg/mL in 
addition to the 15 mg/mL used for i.p. injection. All luciferin solutions were sterile 
filtered using 22-µm syringe filters. Mice were injected i.p. with the same volume of 15 
mg/mL D-luciferin solution as in full body imaging, but were only allowed 5 min to 
recover before being sacrificed. Lungs of the mice were then perfused with the 150 
µg/mL D-luciferin solution by cutting the left atrium and injecting the D-luciferin 
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solution into the right ventricle. The lungs were then excised and placed in the wells of a 
12-well plate containing 1 mL of 300 µg/mL D-luciferin solution and imaged 
immediately on the IVIS Spectrum.  
Statistical Analysis 
Data were shown as mean ± standard error of mean (SEM) whenever the mean 
was the primary value representing a sample group’s behavior. Two group comparison of 
means was accomplished using a 2-tailed Student’s t test, and three group comparisons of 
means was accomplished using a two tailed ANOVA followed by Tukey multiple 
comparisons test. Survival data were analyzed using the Mantel-Cox log-rank test. All 
such comparisons were performed using GraphPad Prism 5 software (Graphpad Software 
Inc., San Diego, CA). p≤0.05 was considered statistically significant for all tests.   
2.5.2 RESULTS 
4T1-luc2 cells implanted in the 9th mammary fat pad metastasize efficiently to the lungs 
 The growth of 4T1-luc2 tumors was very uniform across all mice and across the 
three groups prior to resection (Figure 2.9B). Tumor radiance, collected from full body 
IVIS Spectrum imaging, and the weights of resected tumors were also very similar 
between groups prior to the onset of treatment (Figure 2.9C). Full body IVIS Spectrum 
imaging 48 h after tumor resection shows only three, faint metastases in the cohort of 27 
mice, two of which appear to be in the lungs (Figure 2.9D). Similar imaging of the mice 
at one week post resection shows 11 of the mice now bearing metastases, 10 of which 
appear to lie in the lung fields (Figure 2.9E). At this point, none of the mice exhibit local 
recurrence. Between all of the groups at the conclusion of the study, 21 out of the 28 
mice were found to be bearing lung metastases detectable on ex vivo IVIS or visible at 
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necropsy. In the vehicle control group, eight of the nine mice developed lung metastases, 
fulfilling the goal of achieving ≥80% metastasis formation in the absence of adjuvant 
treatment (Figure 2.9F).  
Two weeks of emodin treatment decreased both metastasis number and metastatic burden 
After one week of daily emodin or vehicle treatment, the three mice with the 
highest lung field luminous flux from each group on IVIS Spectrum imaging were 
sacrificed, and their lungs were imaged ex vivo (Figure 2.10A). Both the full body and ex 
vivo lung imaging showed that there were no differences in total radiance between the 
selected mice from the three treatment groups (Figure 2.10B). Lungs were then fixed in 
4% paraformaldehyde (PFA) for 48 h, imbedded in paraffin, and sectioned. Sections at 
200 µm intervals were stained with hematoxylin and eosin (H&E) and metastases were 
counted and quantified using ImageJ software. The total metastatic volume per total lung 
volume was measured and termed the “metastatic index”. The number of metastases per 
lung section area was also quantified. It was found that while there was no statistically 
significant difference in the metastatic index or number of metastases per mm2 between 
these three groups, there was a trend toward a decreasing number of metastases per unit 
lung area with increasing emodin dosage (Figure 2.10C).  
The mice receiving two weeks of emodin treatment exhibited a strong decreasing 
trend in lung field luminous flux with increasing emodin dose (Figure 2.10D&E). Lung 
section metastasis quantification yielded evidence of a significant decrease in both 
metastatic index and number of metastases per unit lung section area for the 40 mg/kg 





 These data show that, though the trials described above, we have developed a 
reliable method to mimic the clinically observed phenomenon of metastatic recurrence 
from disseminated micrometastases and circulating tumor cells after primary surgical 
removal of the tumor. This model allows for the testing of adjuvant therapies for their 
effectiveness in slowing or preventing recurrence, which is a much more clinically 
relevant therapeutic goal than simply reducing the growth of a primary tumor or limiting 
the metastatic spread of a tumor that is allowed to remain in the body long after it would 
have been diagnosed and removed. Here this model was used to test emodin, but any 
number of adjuvant or neoadjuvant therapies can be screened using this model. It could 
also be adapted to humanized mouse models in the future to further increase the clinical 
relevance of tested treatment paradigms. The availability of a murine model that 
addresses goals relevant to human breast cancer treatment is necessary for effective pre-
clinical screening of proposed therapies.  
 This final iteration of the model has also demonstrated that emodin can effectively 
reduce both metastatic burden and number when administered as an adjuvant therapy. 
This is likely due to both the direct effects of emodin on TAMs observed previously in 
our lab as well as the interference with tumor-promoting TAM-tumor cell crosstalk [118]. 
It is likely that other mechanisms may also be at play, and further studies of such 






Table 2.1 Antibodies for flow cytometry.  
Antibody Product # Company 
CD45 (PE/Cy7) 103113 Biolegend 
CD3 (APC/Cy7) 100221 Biolegend 













Figure 2.1 10 days of tumor growth was insufficient to achieve an appropriately 
high metastatic rate with 4T1-luc2-RFP cells. A, Timeline of this experiment. 7-week-
old, female BALB/c mice received 2x105 4T1-luc2-RFP cells, bilaterally, in the 4th pair 
of mammary fat pads. Tumors were resected as indicated on the timeline, and treatment 
with either 2% DMSO in PBS (vehicle), 20 mg/kg emodin, or 40 mg/kg emodin was 
administered i.p. daily for two weeks post surgery, then every other day for two more 
weeks. B, Tumor growth was monitored until tumor resection, there were no differences 
in measured tumor volume between groups. C, IVIS imaging of mice prior to tumor 
removal and lung field radiance. D, IVIS imaging of mice after tumor removal and lung 
field radiance. E, IVIS imaging of mice on Day 26 since tumor cell implantation; lung 
metastases are visible. F, Percentage of mice in each treatment group to ever develop 











Figure 2.2 Metastases did not occur preferentially in the lungs. A, Percentages of 




Figure 2.3 Mice were able to recover from surgery and metastases appeared 





Figure 2.4 Emodin treatment showed a decreasing trend in metastatic burden and 
an increasing trend in overall survival. A, Lung field IVIS data from Days 9-26 since 
tumor cell implantation. Day 21 where mice began to die from their disease is indicated. 
B, Percentage of mice bearing metastasis in each treatment group based in IVIS data. C, 
Overall survival of each treatment group for the duration of the experiment. D, The final 
IVIS image obtained, 48 days since tumor cell implantation. E, Lung CD8+ T cell flow 











Figure 2.5 The metastatic tropism of 4T1-luc2-RFP cells following primary tumor 
resection is not lung-specific. A, Timeline of this experiment. 8 week-old, female 
BALB/c mice received 2x105 4T1-luc2-RFP cells, bilaterally, in the 4th pair of mammary 
fat pads. Tumors were resected as indicated on the timeline at 3 time-points in order to 
determine the duration of tumor growth necessary for metastatic dissemination. B, 
Average tumor volume per group; there were no differences in measured tumor volume 
between groups. C, Tumor radiance from IVIS imaging by resection group. D, Average 
tumor weights at each removal date. E, IVIS images showing tumor removal and 










Figure 2.6 Gross lung metastases only developed after 26 days of tumor growth 
before resection. A, Lungs of mice remaining alive at the study endpoint (Day 53) with 
surface metastases indicated. B, Quantification of lung surface metastases per mouse. 






Figure 2.7 4T1-luc2 cells metastasize almost exclusively to the lungs. A, Timeline of 
this experiment. 8-12 week-old, female BALB/c mice received 2x105 4T1-luc2 cells in 
the 4th right (9th) mammary fat pad. Tumors were resected as indicated on the timeline, 
and treatment with either 2% DMSO in PBS (vehicle) or 40 mg/kg emodin was 
administered i.p. daily for the duration of the study. B, Pre-surgery tumor IVIS image, 







Figure 2.8 Emodin increased overall survival in lung metastasis bearing mice. A, 
Tumor and lung field radiance prior to resection (Day 28); no difference is observed 
between treatment groups in either parameter. B, Lung field radiance after tumor 
removal, again showing no difference between treatment groups. C, Overall survival of 












Figure 2.9 4T1-luc2 cells implanted in the 9th mammary fat pad metastasize 
efficiently to the lungs. A, Timeline of this experiment. 7 week-old, female BALB/c 
mice received 2x105 4T1-luc2 cells in the 4th right (9th) mammary fat pad. Tumors were 
resected as indicated on the timeline, and treatment with either 2% DMSO in PBS 
(vehicle), 20 mg/kg emodin, or 40 mg/kg emodin was administered i.p. daily for the 
duration of the study. B, Average tumor volume per group; there were no differences in 
measured tumor volume between groups prior to treatment. C, Pre-surgery IVIS image, 
tumor weight, and tumor radiance by group. D, Post-surgery lung field radiance, Day 25. 
E, Post-surgery lung field radiance, Day 30. F, Proportions of mice with lung metastases 
visible on IVIS at Day 30 since tumor cell implantation. Results are shown as means ± 












Figure 2.10 Two weeks of emodin treatment decreased both metastasis number and 
metastatic burden. A, Ex vivo IVIS image of lungs from 3 mice per group with the 
largest metastases after 1 week of treatment. B, In vivo and ex vivo IVIS data showing no 
differences between groups. Results are shown as means ± SE (n=3). C, Quantification of 
metastases from serial lung sections from these 3 mice. D, Ex vivo IVIS image of lungs 
from remaining mice after 2 weeks of treatment. E. Ex vivo IVIS data from these mice. F, 
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Quantification of metastases from the final 6 mice and representative lung section 





EMODIN AS AN AGENT TO PREVENT BREAST CANCER POST-SURGERY 
METASTATIC RECURRENCE 
3.1 BACKGROUND 
 Breast cancer is still the second leading cause of cancer-related death among 
women worldwide. Triple-negative breast cancer has remained difficult to treat, and 
clinical outcomes are very poor, especially if the cancer has metastasized [3]. Our lab has 
established that emodin, an anthraquinone derived from herbs used in traditional Chinese 
medicine, is capable of modulating macrophage activation and interfering with the tumor-
promoting feedback loop between tumor cells and macrophages, leading to decreased 
metastatic dissemination and decreased tumor growth [103, 118, 120]. Emodin, like 
many other naturally derived compounds, is inexpensive and capable of affecting 
multiple pathways simultaneously [121-123]. It has also demonstrated very low toxicity 
[104]. There are currently no cancer treatments specifically targeting macrophages or 
innate immunity. Thus emodin may prove complementary to other immune therapeutic 
strategies, the majority of which are intended to boost adaptive immunity. The generally 
immune suppressive tumor microenvironment fostered by M2-like tumor associated 
macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells 
(Tregs) hampers existing antitumor immunity and decreases the effectiveness of immune 
therapeutic strategies. Some therapies meant to address this general immune suppression 
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have proven effective in the laboratory setting, but none have yet progressed to clinical 
use [124-126].  
In order to help bridge this gap, we have performed a study investigating 
emodin’s effectiveness as an adjuvant chemotherapy for triple negative breast cancer. 
The relative pattern of human breast cancer treatment was mimicked in this murine 
model with surgical resection before macrometastases were visible, followed by emodin 
treatment and recurrence monitoring. In this model, as is often the case with human 
cancer treatment, the primary tumor is removed prior to the initiation of chemotherapy, 
therefore the therapy is meant to only affect any residual tumor tissue, either at the 
primary sites or disseminated to the circulation or distant organs. However, the immune 
suppressive environment engineered by the tumor for its own protection is diminished for 
a brief period, but still present following resection, and is still capable of aiding in the 
survival of any established or circulating tumor cells and reducing the success of immune 
therapeutic strategies [127]. Here we show that through emodin’s direct effects on these 
remaining tumor cells and its effects on macrophages, metastatic recurrence of triple 
negative breast cancer is significantly degreased, and overall and metastasis-free survival 
are both increased. The mechanism for this is at least in part related to the direct and 
indirect modulation of cancer cell epithelial to mesenchymal transition (EMT) by 
emodin. We show that emodin can directly decrease transforming growth factor-β (TGF-
β) production by TAMs which in turn reduces tumor cell EMT. Acting in this way, 
emodin can both reduce the ability of circulating and newly arrived cancer cells to 
effectively establish metastases and help to counteract the systemic immune suppression 
imposed by the primary tumor.  
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3.2 DETAILED METHODS 
Tumor cell culture and conditioned medium collection 
EO771 tumor cells were obtained in 2012 and 4T1 cells were obtained from the 
American Type Culture Collection (ATCC) in 2013 and were expanded in high-glucose 
Dulbecco’s modified eagle medium DMEM supplemented with 10% fetal bovine serum 
(FBS), 100 U/mL penicillin (Sigma-Aldrich Corp.), and 100 µg/mL streptomycin 
(Sigma-Aldrich Corp.) in a 37˚C, humidified, 5% CO2 incubator. Tumor conditioned 
medium was collected by first culturing tumor cells expanded to 70% or 90% confluence 
for EO771 and 4T1 cells, respectively, in T-75 bottles (Corning Inc., Corning, NY). 
Medium was then removed, plates were gently rinsed once with phosphate-buffered 
saline (PBS), and 10 mL of serum-free DMEM containing penicillin and streptomycin 
(P/S) was added. Cells were cultured for 48 h in this medium, which was then collected, 
centrifuged at 350 x g for 5 min to remove large cellular debris, and filtered through a 45-
µm vacuum filter (Corning Inc.). This medium was then concentrated using 3-kD 
molecular weight cutoff centrifuge concentrators (Sigma-Aldrich Corp.) to 25X. Aliquots 
were stored at -80˚C for later use. To treat macrophages, conditioned medium was diluted 
1:5 in fresh serum-free DMEM and termed tumor-conditioned medium (TCM).  
Peritoneal macrophage harvesting and conditioned medium collection 
Mice were injected intraperitoneally (i.p.) with 4% Brewer thioglycollate at a 
volume of 100 µL/g of mouse body weight. Three days later mice were sacrificed and 
macrophages were collected by peritoneal lavage using 20 mL ice-cold PBS. Peritoneal 
cells were plated in DMEM + 10% FBS + P/S and cultured in a 37˚C, humidified, 5% 
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CO2 incubator for 1 h, at which time non-adherent cells were rinsed away. The adherent 
macrophages were then cultured overnight in serum-free DMEM before treatment.  
 Treatment consisted of 24 h in 4T1 or EO771 tumor cell-conditioned medium 
(depending on whether macrophages were obtained from BALB/c or C57BL/6 mice, 
respectively). This medium was either supplemented with emodin at 25 µM or DMSO as 
a vehicle control. After this 24 h treatment, macrophages were rinsed and cultured in 
serum-free DMEM for an additional 48 h. This macrophage-conditioned medium was 
then collected and used immediately to treat the tumor cell line of the corresponding 
background.  
Non-contact macrophage/tumor cell co-culture 
1x105 4T1 or EO771 tumor cells were seeded in 24-well plates in serum-free 
DMEM. 1x105 syngenic murine macrophages, previously treated for 24 h with TCM with 
or without 25 µM emodin, were seeded in trans-well inserts with 8-µm-pore polyethylene 
terephthalate membranes (Corning Inc.). This non-contact co-culture setup was placed in 
a 37C, 5% CO2 incubator for 48 h. At the end of this incubation period, the tumor cells in 
the bottom chamber were rinsed with PBS and lysed with Qiazol (Qiagen, Hilden, 
Germany) for RNA extraction and qPCR.  
Trans-well invasion assay 
Tumor cell invasion capacity was tested by determining their ability to migrate 
through Matrigel® Basement Membrane Matrix (Corning Inc.). To do this, 100 µL ice-
cold Matrigel was added to the inside of trans-well inserts with 8-µm polyethylene 
terephthalate membranes which fit into the wells of 24-well plates (Corning). Matrigel-
containing trans-well inserts were then incubated at 37˚C for 30 min to allow the Matrigel 
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to solidify. 300 µL of DMEM + with 10% FBS, as a chemoattractant, or serum-free 
DMEM was added to wells of 24-well plates followed by the Matrigel-containing trans-
well inserts. 1x105 4T1 or MDA-MB-231 breast tumor cells were seeded on top of the 
Matrigel inside the trans-well inserts in serum-free DMEM. Prior to this seeding, tumor 
cells had been pretreated with either 0.05% DMSO (as vehicle control), 6 ng/mL TGF-
β1, 25 µM emodin, 6 ng/mL TGF-β1 + 25 µM emodin, or, for 4T1 cells, conditioned 
medium from macrophages treated with either 4T1-conditioned medium, 25 µM emodin, 
or both. The base medium for all pretreatments was serum-free DMEM.  
Migration assay 
4T1 or MDA-MB-231 cells were cultured in DMEM 10% FBS+P/S to confluency 
in 12-well plates. A scratch was then made through the layer of cells with a sterile pipette 
tip. Various treatment media were applied for 16 h, at which time the amount that the 
tumor cells had migrated in to fill the gap was measured using ImageJ software. The 
treatment media consisted of serum-free DMEM supplemented with either 0.06% DMSO 
(as vehicle control, also included in all other treatments in this list), 25 µM emodin, 6 
ng/mL TGFβ1, and 6 ng/mL TGFβ1 + 25 µM emodin. Tumor cells were also treated with 
macrophage-conditioned medium from macrophages treated with either 4T1-condioned 
medium or 4T1-condiioned medium + 25 µM emodin as described previously.   
RNA extraction and quantitative real-time PCR 
For RNA extraction, cells were lysed with TRIzol reagent (Thermo Fisher 
Scientific, Waltham, MA). RNA was then extracted by precipitation according to the 
manufacturer’s protocol. Briefly, 0.5 mL isopropanol was added to the 1 mL TRIzol, 
incubated at RT for 10 min, and centrifuged at 12,000 x g at 4˚C for 10 min. Supernatant 
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was discarded, and the resulting pellet was washed in 1 mL 75% ethanol, then 
centrifuged for 5 min at 7,500 x g at 4˚C. Supernatant was again discarded and the pellet 
was allowed to air dry. RNA pellets were resuspended in 20 µL of RNase-free water and 
heated at 60˚C for 10 min. RNA concentration was measured using an Evolution 60 
spectrophotometer (Thermo Fisher Scientific). cDNA was then synthesized using 1 µg 
RNA, or the maximum amount possible if less than 1 µg, using iScript cDNA Synthesis 
Kits (Bio-Rad Laboratories, Hercules, CA). qPCR was performed using iQ SYBR Green 
Supermix (Bio-Rad Laboratories). All cDNA stocks were diluted 1:25, and 10 µL of the 
resulting solution was used for each qPCR reaction. Primers are listed in table 3.1. qPCR 
run conditions were 95˚C for 5 min followed by a repeated cycling of 95˚C for 10 sec, 
58˚C for 15 sec, and 72˚C for 20 sec. A melt curve was then collected through the 
following temperature fluctuations: 95˚C for 10 sec, 65˚C for 5 sec, and terminating 
again at 95˚C. All samples were run in duplicate using a Bio-Rad CFX Real Time 
thermocycler. The ΔΔCt method was used to determine relative expression.  
Western Blotting 
For protein extraction, cultured tumor cells were lysed in RIPA buffer (Pierce, 
Rockford, IL) supplemented with 1:100 protease inhibitor cocktail and 1:100 phosphatase 
inhibitor cocktail (Sigma-Aldrich Corp.). Protein was quantified using the Lowry 
method, and loaded into 10% SDS-PAGE precast gels (Bio-Rad Laboratories). Protein 
was the transferred onto nitrocellulose membranes (Sigma-Aldrich Corp.). Membranes 
were probed with indicated primary antibodies (Cell Signaling Tech. Danvers, MA), then 
the corresponding secondary antibodies (Santa Cruz Biotech. Dallas, TX) conjugated to 
horseradish peroxidase. Protein was detected using ECL kits (Pierce) and signal 
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intensities were quantified using Image-Pro Plus analysis software (Media Cybernetics, 
Rockville, MD) 
Flow cytometry 
Flow cytometry was performed for both in vitro and in vivo experiments. For in 
vitro experiments, peritoneal macrophages were removed from plates using Accutase 
(Biolegend). Single cell suspensions of 1x106 cells in 100 µL PBS were blocked with 
CD16/32 blocking antibodies (Biolegend) at a concentration of 2.5 µg/mL for 10 min at 
4˚C. Cells were then stained with anti-CD206 PE for 30 min at 4˚C.  
Lymph node cells were dissociated using 70-µm cell strainers (Corning), rinsed, 
counted, and 1x106 cells were suspended in 100 µL PBS for staining. Lymph node cells 
were blocked with anti-CD16/32 antibodies as described and surface stained with the 
following markers for 30 min at 4˚C: anti-CD45 PE-Cy7, anti-CD11c PE, anti-CD3 
APC-Cy7, anti-CD4 APC, anti-CD8 FITC, anti-CD69 PE, and anti-CD103 FITC. 
Internal staining was performed using a BD Cytofix/Cytoperm Fixation Permeabilization 
Kit (BD Biosciences) according to the manufacturer’s instructions. The antibodies used 
to stain intracellular antigens were anti-IFNγ PE and anti-FOXP3 PE, each at a 
concentration of 4 µg/mL in the manufacturer specified buffer.  
All samples were washed twice with PBS after staining and resuspended in 500 
µL PBS for flow cytometry. Samples were analyzed on a BD FACS Aria II using FACS 
Diva software (BD Biosciences). 10,000 to 100,000 events were collected for each 





Orthotopic tumor model and surgical resection 
7-week-old, female BALB/c mice were housed at the University of South 
Carolina Animal Research Facility; all procedures were approved by the Institutional 
Animal Care and Use Committee. At 8 weeks of age, 4T1-luc2 cells (PerkinElmer) were 
suspended in PBS at a concentration of 1x107 cells/mL and 2x105 cells were implanted 
into the 9th mammary fat pad of each mouse as described previously. Tumor size was 
monitored and measured every 3-4 days beginning on Day 10 after implantation. The 
following equation was used to calculate tumor volume: (short axis)2 x (long axis)/2 ≈ 
volume. The tumors were removed according to the following procedure on Day 21: each 
mouse was anesthetized using an isoflurane vaporizer, and maintained under anesthesia 
for the duration of the surgery with the vaporizer set to deliver 2% isoflurane. The 
surgical field was cleaned liberally with 70% ethanol and betadine swabs. A 1-2 cm 
incision was made medial to the tumor, and the tumor, with as much surrounding fat pad 
as possible, was resected. An electrocautery unit was on hand to stop excess bleeding if 
necessary. Incisions were closed with stainless steel clips and suture. Mice were allowed 
to recover in a cage heated to 30˚C. Immediately following surgery, the three groups of 
mice received i.p. injections of PBS with 2% DMSO by volume containing either 0 
mg/kg, 20 mg/kg or 40 mg/kg emodin. The volume of these injections was ~800 µL per 
mouse. These i.p. injections were administered daily for the next 17 days. On the 17th day 
after tumor resection (38th day since tumor cell implantation), the mice were anesthetized 
with isoflurane and sacrificed by cervical dislocation. Lungs and lung-draining lymph 




In vivo IVIS imaging 
BALB/c mice bearing 4T1-luc2 tumors were imaged using an IVIS Spectrum 
(PerkinElmer). D-luciferin (Sigma-Aldrich Corp.) was dissolved in PBS at a 
concentration of 15 mg/mL. Mice received 10 µL of this solution per gram body weight 
intraperitoneally (i.p.), were anesthetized using an isoflurane vaporizer, and images were 
obtained at 600 nm wavelength 10 min after receiving the D-luciferin injection. 
Metastatic recurrence and primary tumor size were monitored using the IVIS Spectrum to 
image the luciferase activity in the 4T1-luc2 cells using the same imaging procedure 
described here. In vivo IVIS imaging was performed on Days 20, 21, 24, and 30 since 
tumor cell implantation.  
Ex vivo IVIS imaging 
Ex vivo IVIS imaging was intended to generate a more accurate estimate of the 
mice with lung macro-metastases than the in vivo imaging of disseminated tumor in 
which the mouse’s tissue blocked a great deal of the signal and could render relatively 
small metastases undetectable. In order to do this, mice were first injected i.p. with D-
luciferin in PBS in the same manner as with in vivo imaging already described. However, 
mice were allowed 5 min to recover and ensure D-luciferin perfusion following i.p. 
injection. Mice were then anesthetized with isoflurane and sacrificed by cervical 
dislocation. Lungs of mice were immediately perfused with a 150 µM solution of D-
luciferin in PBS, removed, and placed in a solution of 300 µM D-luciferin for imaging. 
All of these solutions were maintained at RT. Lungs were imaged at 600 nm emission 
wavelength for 5 sec, then washed with PBS and fixed in 8 mL 4% paraformaldehyde 




Following PFA fixation for 24-48 h at RT, mouse lungs were paraffin imbedded 
and sections were cut 5 µm thick at 150 µm intervals. Five such sections were obtained 
for each lung pair. These were deparaffinized and stained with hematoxylin and eosin. 
Stained slides were imaged at 10X magnification using an EVOS FL Auto 2 System 
(Thermo Fisher Scientific). Images were tiled in order to view the entire lung using the 
EVOS System software. Size of images was limited such that they did not require 
compression to be saved by the EVOS System software, ensuring that pixels represented 
equivalent real dimensions on every section. Pixel areas of lung tissue and metastases 
were measured for each image by hand using ImageJ software. These pixel values were 
converted to mm2 using the conversion factor 1.142 pixels/µm determined by the 10X 
objective. The number of metastatic nodules per section was also counted. These values 
were used to calculate the following parameters for each lung pair:  Metastasis Index = 
(metastatic volume)/(total lung volume), and Metastasis Number Index = (number of 
metastases per section)/(lung section area).  
Statistical analysis 
Data were shown as mean ± standard error of mean (SEM) whenever the mean 
was the primary value representative of a sample group’s behavior. Three group 
comparison of means was accomplished using a one-way ANOVA followed by Tukey 
multiple comparisons test, while two group comparison was accomplished using a two 
tailed Student’s t test. All such comparisons are performed using GraphPad Prism 5 
software (Graphpad Software Inc.). Differences between proportions were determined 
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using a two tailed N-1 Chi-Square test. p≤0.05 was considered statistically significant for 
all tests.  
3.3 RESULTS 
Adjuvant emodin treatment decreases metastatic recurrence of TNBC after surgical 
resection 
Given our previous results demonstrating the effects of emodin on macrophage-
induced tumor growth and metastatic dissemination, we sought to determine its relevance 
in a model of post-surgical breast cancer treatment. Our model of metastatic recurrence 
involved implanting 4T1-luc2 cells into the 9th mammary fat pads of mice, then removing 
these tumors at a time-point experimentally determined to yield >80% metastatic 
recurrence, yet no local recurrence in untreated mice. The metastases occur almost 
exclusively in the lungs and develop to a detectable extent within 3 weeks after tumor 
resection, again in untreated mice. The timeline and treatment schedule of this model is 
intended to biologically parallel that implemented in human breast cancer treatment, 
where diagnosis is often quickly followed by surgical resection and adjuvant 
chemotherapy (Figure 3.1A). After the implantation of 4T1-luc2 cells, tumors were 
allowed to grow for 21 days, and were imaged using an IVIS Spectrum prior to resection 
(Figure 3.1B). Tumors were surgically removed on Day 21, immediately followed by 
IVIS imaging to confirm that all local tumor tissue had been removed and check for 
detectable metastases (Figure 3.1C). There was one detectable lung metastasis in the 
DMSO only group, and this mouse was excluded from later quantitative analyses. 
Treatment was initiated about 8 h post-surgery and consisted of i.p. injections of PBS + 
2% DMSO, 20 mg/kg emodin, or 40 mg/kg emodin. Emodin was suspended in PBS + 
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2% DMSO for these injections. Mice were divided into three treatment groups based on 
equal average tumor size at resection. This was determined both by tumor radiance 
detected on IVIS and resected tumor weight (Figure 3.1D). There were no differences in 
calculated tumor volume at any point from when tumor size monitoring began on Day 10 
through resection (Figure 3.1D). Metastatic recurrence was tracked by IVIS imaging on 
Days 3 and 9 after surgery (Days 24 and 30 since tumor implantation) (Figure 3.1E&F). 
From the post-surgery IVIS data, it was apparent that tumor cells were present to a lesser 
extent in the lung fields of mice that received emodin treatment. Mice were sacrificed 17 
days after tumor resection (38 days since tumor implantation) for analysis of the 
metastatic microenvironment and the measurement of lung metastatic burden. First, lungs 
were perfused and quickly imaged ex vivo using the IVIS Spectrum, yielding a more 
accurate estimate of metastatic burden than similar imaging through the chest wall 
(Figure 3.1E&G). Lungs were then fixed and 5 sections were taken at 150 µm intervals 
though each lung pair. These were H&E-stained in order to render tumor nodules more 
visible, and both the number and size of metastatic nodules were quantified for each 
section. These values, as well as the total lung area from each section, were used to 
calculate the metastatic index (metastasis volume/total lung volume), the number of 
metastases per mm2 of total lung section area, and the average size of each metastasis. 
The 40 mg/kg emodin dose decreased the metastatic index, the number of metastases, and 
the average size of each metastasis (Figures 3.1H&I). Previous studies of the effect of 
emodin had only focused on the primary tumor microenvironment, but here for the first 
time, we have shown that emodin, when administered only after the primary tumor had 
been  surgically removed, is still able to affect the establishment and growth of distant 
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metastases. Based on IVIS imaging, emodin treatment during this post-surgery period 
could reduce metastatic recurrence at the endpoint of the study to ~64.3% from about 
~84.6% in the control-treated group (Figure 3.1J). These results lend further credence to 
the possibility that emodin has potential as a therapy for both the prevention and arrested 
development of triple negative breast cancer metastasis.  
Emodin modulates the immune microenvironment of the metastatic site 
To gain a more complete understanding of emodin’s effect on the immune 
microenvironment of metastases, lung-draining lymph nodes were collected from the 
mice involved in the adjuvant emodin therapy experiment and analyzed via flow 
cytometry. This revealed some key differences between mice that received emodin and 
those that did not. Chiefly, in both emodin-treated groups (20 mg/kg and 40 mg/kg), there 
was a significant decrease in CD4+FOXP3+ regulatory T cells (Figure 3.2A). It has been 
shown that M2 macrophage-conditioned medium is capable of inducing FOXP3 
expression in naïve human CD4+ T cells [128]. It was further shown that of all the 
cytokines released by the M2 macrophages, TGF-β was found to be the one on which 
CD4+ T cell FOXP3 induction was crucially dependent.  A second key finding is that 
there appear to be less migratory DCs in the tumor draining lymph nodes of untreated 
mice than those treated with 40 mg/kg emodin (Figure 3.2B). Here migratory DCs are 
identified as CD11c+CD103+ cells [129]. Again, a likely contributor to this phenomenon 
is TGF-β, as it has been demonstrated that TGF-β1 has been shown to arrest DCs within 
tumor tissue and prevent migration to lymph nodes where an adaptive immune response 
could be more effectively fostered [130]. Lung sections containing metastases were also 
stained for markers of macrophage presence (CD68) and activation phenotype (Ym1). 
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Less macrophages were present in and around metastatic nodules in the lung tissue of 
mice treated with 40 mg/kg emodin (Figure 3.2C). Ym1+ cells, were also fewer in the 
regions around metastatic nodules in both the 20 mg/kg and 40 mg/kg emodin-treated 
mice compared to the control, indicating a less M2-like phenotype of macrophage 
polarization (Figure 3.2D) [131]. It was also interesting to note the obvious ring of 
macrophages surrounding many developing metastasis (Figure 3.2E).  
These data show that post-surgical emodin treatment is capable of creating a less 
immune suppressed, pro-tumor environment in potential metastatic sites, which in turn 
may account for the reduction in metastatic burden. It is likely that this effect is at least in 
part due to modulation of macrophage activation at sites of metastasis formation resulting 
in a change in the release of cytokines from these macrophages, such as TGF-β, known to 
increase the metastatic success rate of tumor cells [132].  
Emodin inhibits breast tumor cell EMT through modulating macrophage phenotype and 
TGFβ secretion.  
Previous work by our lab and others has shown that tumor associated 
macrophages (TAMs) secrete TGF-β1, and that this can increase the metastatic and 
invasive capabilities of tumor cells through affecting tumor cell epithelial-to-
mesenchymal transition (EMT) [133, 134]. Based on previous observations from our lab 
that emodin suppresses tumor-cell induced M2-like macrophage polarization, an 
activation phenotype associated with increased TGF-β1 secretion, we hypothesized that 
this may be a mechanism by which emodin was able to decrease the establishment of 
distant metastases in our murine breast cancer studies [103, 118]. One of our first steps 
was to determine whether or not emodin affected TAM TGF-β1 secretion. In order to do 
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this, peritoneal macrophages from BALB/c mice were treated with 4T1-conditioned 
medium with or without 25 µM emodin for 24 h. Our previous work has indicated that 
this concentration is similar to the serum emodin levels in mice treated with 40 mg/kg 
emodin administered i.p. [118] qPCR showed that tumor-conditioned medium treatment 
increased TGF-β1 expression, and this was abolished when emodin was added. Emodin 
alone had little or no effect on macrophage TGF-β1 expression (Figure 3.3A). To further 
confirm this relationship in vitro, conditioned medium was collected from macrophages 
treated in the same way and ELISA was performed for TGF-β1. Emodin treatment 
suppressed the tumor-conditioned medium-induced increase in TGF-β1 protein release 
(Figure 3.3B). It is important to note that this increase in TGF-β1 transcription coincided 
with a transcriptional profile indicative of M2-like macrophage polarization.   
After demonstrating that emodin has the ability to interfere with TAM TGF-β1 
production at physiologically achievable concentrations, it is important to also determine 
whether or not this interference could lead to changes in tumor cells which affect 
metastatic potential, such as the EMT status of tumor cells. To do this, peritoneal 
macrophages from BALB/c and C57BL/6 mice were pretreated with serum-free DMEM 
supplemented with tumor-conditioned medium from syngenic tumors with or without 25 
µM emodin. Macrophage treatment with 0.05% DMSO in serum-free DMEM was used 
as a vehicle control. The macrophages were then co-cultured with syngenic tumor cells 
using a trans-well setup such that the two cell populations could not directly contact one 
another but shared the same medium (Figure 3.3C). After 24 h of co-culture with 
macrophages, qPCR on the tumor cells showed that multiple indicators of EMT, such as 
N-cadherin and vimentin, exhibited increased expression in the tumor cells co-cultured 
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with macrophages that had been exposed to syngenic tumor conditioned medium only 
(Figures 3.3D&E). The addition of emodin to this tumor-conditioned medium restored 
tumor cell EMT marker expression back to levels similar to co-culture with control-
treated macrophages (Figures 3.3D&E). Other genes indicating a shift from an 
epithelial-like to a mesenchymal-like phenotype also exhibited a similar pattern, 
including matrix metalloproteinases 2 and 9 (MMP2 and MMP9) and fibronectin 
(Figures 3.3D&E). Macrophage pretreatment with emodin alone had varying effects on 
the levels of these EMT markers (Figures 3.3D&E). Taken together, these results show 
that while tumor cells can condition macrophages to exhibit a more M2-like phenotype 
and secrete increased levels of EMT-promoting TGF-β1, the addition of emodin can 
counteract both M2-like polarization and TGF-β1 secretion in macrophages. This in turn 
leads to an inhibition in TAM-induced EMT in breast tumor cells.  
Emodin inhibits TGF-β and tumor-associated macrophage-induced migration and 
invasion of tumor cells 
In our adjuvant therapy model, the primary tumor is never exposed to emodin, so 
the observed differences in metastatic burden must be due to either effects on circulating 
tumor cells’ ability to initiate metastases, newly established micrometastases, or the 
microenvironment at the metastatic site. An important, enabling trait for the formation of 
distant metastases is tumor cell invasion/migration. In order for tumor cells to both 
escape the primary tumor, enter the vasculature, and to extravasate once at the metastatic 
site, they must have sufficient invasive and migratory potential. This motility is enhanced 
by EMT, a prime driver of which is TGF-β1 [135]. As expected, TGF-β1 treatment 
drastically increased the migratory capacity of 4T1 cells in a scratch migration assay 
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(Figure 3.4A&B). When 25 µM emodin was added to the TGF-β1 treatment, migration 
ability was reduced back to control-treated levels. Again, emodin alone had little to no 
effect on the tumor cells’ ability to migrate. This experiment was also performed with the 
human breast cancer cell line, MDA-MB-231. Emodin again reduced the TGF-β1-
induced tumor cell migration, but in this case, emodin alone also seemed to reduce the 
migration ability of the cells (Figure 3.4B).  
In order to more firmly establish the connection between macrophage-released 
cytokines and these changes in migration, a similar scratch migration assay was 
performed on 4T1 cells treated with various macrophage-conditioned media. 
Macrophages were pretreated with either DMSO as vehicle control, 25 µM emodin in 
DMSO, 4T1-conditioned medium + DMSO, or 25 µM emodin in DMSO + 4T1-
condiitoned medium. After this pretreatment, macrophages were washed to remove 
emodin and 4T1-conditioned medium then cultured in serum-free DMEM, which was 
collected as macrophage-conditioned medium. This was an attempt to isolate to effects of 
emodin on the cytokines secreted by the macrophages from the direct effects of emodin 
on the tumor cells. The results of this assay showed that the conditioned medium from 
macrophages treated with 4T1-conditioned medium drastically increased the migration of 
tumor cells, and the addition of emodin decreased migration back to control-treated levels 
(Figure 3.4C&D). Pretreatment of macrophages with emodin alone had little effect on 
subsequent tumor cell migration.  
To further test this signaling loop in another model of tumor cell motility, 
Matrigel® invasion assays were performed. These were intended to test the hypothesis 
that emodin could affect tumor cells’ ability to move through a network of ECM proteins, 
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an attribute closely linked to EMT and crucial for both tumor cells leaving the primary 
tumor and establishing themselves as distant metastases. Our results from these 
experiments were similar to those from the scratch-migration assays, and indeed were 
performed under similar conditions. Again TGF-β1 directly increased tumor cell 
invasion, and 25 µM emodin was able to directly decrease this effect back to baseline in 
both murine and human breast cancer cell lines (Figure 3.4E&F). Treating tumor cells 
with conditioned medium from macrophages that had been exposed to 4T1-conditioned 
medium also increased their invasive capacity, and this effect was again reversed by the 
addition of emodin to the macrophage pretreatment (Figure 3.4G&H). Taken together 
these results show that not only is emodin capable of skewing macrophage activation 
phenotype such that less EMT-inducing TGF-β1 is produced, it is also capable of 
reducing the EMT-promoting effects of TGF-β1 on tumor cells.  
The intent of these in vitro studies is to focus on the potential effects that emodin 
may be exhibiting in vivo on the ability of tumor cells to extravasate and establish 
themselves in the lungs. Previous intravital imaging studies have shown that one of the 
first steps of extravasation involves the extension of structures termed invadopodia 
through the endothelium into the extravascular space [136]. These invadopodia are 
enriched for proteins such as cortactin, Tks4, and Tks5, and proteases such as MMP9 and 
MMP2 [136, 137]. Inhibition of invadopodia-related proteins, such as Tks5 has been 
shown to reduce breast tumor progression and metastasis [136, 137]. Given our 
observations that emodin is able to both decrease metastatic recurrence when 
administered as an adjuvant therapy, in the absence of the primary tumor, and decrease 
migration and invasion of tumor cells in response to cytokines including TGF-β1 released 
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by tumor-exposed macrophages, it is likely that emodin is affecting tumor cells’ ability to 
extravasate and establish metastases in vivo. We have already demonstrated the ability of 
emodin to reduce the ability of tumor-exposed macrophages to initiate MMP2 and MMP9 
expression in tumor cells (Figure 3.3E&F). We further show that both cortactin and 
Tks5 expression are reduced in EO771 tumor cells when exposed to conditioned medium 
from macrophages pretreated with both emodin and EO771-condioned medium versus 
the tumor-conditioned medium alone, indicating decreased formation of invadopodia-like 
structures (Figure 3.3I). In addition to this finding, Emodin was also capable of 
significantly decreasing Notch1 expression in EO771 tumor cell/macrophage non-contact 
co-culture (Figure 3.3I). It has been shown that macrophages induce the formation of 
invadopodia and extravasation of tumor cells via Notch1 signaling [138].  
Emodin interferes with both TGF-β canonical and non-canonical signaling in tumor cells 
 TGF-β binding to its receptors largely results in signaling through two branching 
cascades referred to as the canonical and non-canonical signaling pathways. The 
canonical pathway occurs largely downstream of a phosphorylated Smad2/3 complex, 
while the non-canonical pathways are more broadly branching and have been defined as 
all non-Smad TGF-β signaling pathways, including but not limited to MAP kinase 
pathways and PI3K/Akt pathways [139]. A number of these non-canonical functions have 
been linked to EMT, and we examine several in our efforts to determine where emodin is 
interfering in the complex web of TGF-β signaling.  
We have shown that emodin decreases TGF-β1 secretion from macrophages 
exposed to tumor-conditioned medium and that emodin can interfere with TGF-β1’s 
induction of a pro-metastatic tumor cell phenotype. Others have shown that emodin is 
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capable of interfering with TGF-β canonical signaling in human cervical cancer cells 
[140], but neither its effects on the canonical nor the non-canonical pathways of TGF-β 
signaling in breast cancer have been demonstrated. In order to assess canonical TGF-β 
signaling, we determined the level of Smad2/3 phosphorylation, which should increase in 
response to TGF-β. We found that the ratio of phosphorylated to total (p/t) Smad2/3 is 
increased by TGF-β, as expected, and is decreased by the addition of 25 µM emodin in 
both mouse and human breast cancer cell lines (Figure 3.5A-C). Akt is phosphorylated 
as a component of non-canonical TGF-β signaling leading to induction of EMT in tumor 
cells [141]. The addition of emodin to TGF-β treatment decreased its phosphorylation, 
though not to a statistically significant degree (Figure 3.5D). STAT3 signaling has 
previously been shown to be required for TGF-β-induced EMT in other tumor models 
[142]. Here we show that its phosphorylation in 4T1 cells in increased in response to 
TGF-β and decreased back to control levels by the addition of emodin (Figure 3.5D). 
Finally the transcription factors Twist and Zeb1, both of which are induced by TGF-β 
signaling and are important for EMT in various tumors including breast cancer [143, 
144], exhibit decreased expression upon the addition of 25 µM emodin to TGF-β 
treatment in 4T1 cells (Figure 3.5E). Thus emodin interferes with many aspects of both 
canonical and non-canonical TGF-β signaling pathways in breast tumor cells.  
3.4 DISCUSSION 
Our data show that adjuvant emodin is capable of preventing metastatic 
recurrence and slowing the progression of existing metastatic disease in a murine model 
of triple-negative breast cancer. Emodin reduced both the size and number of metastases 
and increased overall and recurrence-free survival when administered shortly after tumor 
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resection in mice not yet presenting with detectable lung metastases. It was also capable 
of eliciting changes in the frequency of Tregs (CD4+FOXP3+) and migratory DCs 
(CD11c+CD103+) in lung-draining lymph nodes, both of which have been linked to 
decreased TGF-β1 signaling. Further investigation showed that indeed emodin treatment 
was capable of reducing TAM TGF-β1 production, due at least in part to its ability to 
decrease macrophage M2-like polarization. Macrophages pulsed with tumor-conditioned 
medium increased tumor cell migration and invasion as well as markers of EMT: all 
parameters linked to improvements in the ability of tumor cells to establish metastases. 
When emodin was added to this macrophage pretreatment, all three of these phenotypic 
markers were significantly decreased, indicating that the changes elicited by emodin 
treatment in macrophage cytokine release were capable of imparting less metastatic 
tumor cells. In addition to acting through macrophages, emodin also exhibited direct 
effects on tumor cell response to TGF-β1. Treatment of tumor cells with TGF-β1 
increased marker of EMT, migration, and extracellular matrix invasion as expected, and 
addition of emodin again restored tumor cell phenotype to near baseline. It has recently 
been discovered that emodin is capable of down-regulating TGF-β signaling in pancreatic 
and cervical cancer cells, but its effect on this pathway in breast tumor cells has not been 
investigated [140, 145]. Further investigation showed that emodin was able to interfere 
with both the canonical and non-canonical pathways of TGF-β1 signaling in several 
breast tumor cell lines. Thus emodin is capable of not only reducing TGF-β1 secretion 
from TAMs, it also reduces tumor cell response to TGF-β1 by inhibiting its signaling 
cascades. These effects combine to render tumor cells much less capable of establishing 
distant metastases.  
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The majority of literature focused on the effects of emodin on cancer describes 
only its direct effects on tumor cell viability or phenotype [98, 146]. Our lab has 
previously detailed emodin’s interference with the cross-talk between tumor cells and 
macrophages. This feedback loop leads to the promotion of tumor growth and immune 
suppression [118]. Furthermore, the concentrations of emodin found to be tumoricidal 
were not achievable in serum in our murine models [103]. There have also been a number 
of studies in recent years showing that emodin is capable of interfering with TGF-β1 
signaling in several cell types, including a few tumors, though results of these studies are 
mixed [7, 140, 145]. Some show that emodin has no effect on TGF-β signaling [147]. A 
single study has shown that emodin is capable of decreasing tumor cell migration and 
invasion as well as MMP-2 and MMP-9 secretion in MDA-MB-231 human breast cancer 
cells. This study also demonstrated that emodin treatment decreased lung metastasis in 
athymic mice implanted with MDA-MB-231 cells [148]. By employing athymic mice, 
this study was able to determine the in vivo effects of emodin on a model of human breast 
cancer, but the resulting picture is incomplete as immune cell interaction with tumor cells 
is crucial for tumor growth and metastasis, and is certainly important for human cancer 
patients. Our findings that emodin affects the production of TGF-β by TAMs, thus also 
indirectly reduces metastatic capacity, are novel. An in vitro-only study has shown that 
emodin can interfere with TGF-β signaling from the fibroblasts collected from patients 
with triple-negative breast cancer and a human breast cancer cell line, BT20 [132]. This 
study found that pretreating the isolated fibroblasts with emodin inhibited BT-20 cell 
EMT in a direct co-culture system. This direct co-culture model, however, does not limit 
79 
 
the interactions between fibroblasts and tumor cells to only soluble mediators. Our 
indirect co-culture model simply and effectively enforces this limitation.  
The major novelty of this study is the implementation of emodin as an adjuvant 
therapy in a model biologically mimicking the pattern of human breast cancer treatment. 
Showing that emodin is capable of decreasing metastatic recurrence when the primary 
tumor has been removed prior to treatment is valuable knowledge that bolsters emodin’s 





Table 3.1 Antibodies for flow cytometry 
Antibody Product # Company 
CD45 (PE-Cy7) 103113 Biolegend 
CD3 (APC-Cy7) 100221 Biolegend 
CD4 (APC) 100411 Biolegend 
CD8 (FITC) 100803 Biolegend 
CD69 (PE) 104507 Biolegend 
IFNγ (PE) 505807 Biolegend 
FoxP3 (PE) 126403 Biolegend 
CD11c (APC) 117309 Biolegend 
CD103 (PE) 121413 Biolegend 
 
Table 3.2 Antibodies for Western Blot/Immunohistochemistry 
Antibody Procedure Product # Company 
Rb-α-Ym1 IHC 60130 Stemcell 
Gt-α-rb Alexa Fluor 488 IHC A11008 Invitrogen 
t-SMAD2/3 Western 5678S Cell Signaling Technology 
p-SMAD2/3 Western 8828S Cell Signaling Technology 
t-STAT3 Western 12640S Cell Signaling Technology 
p-STAT3 Western 9145S Cell Signaling Technology 
t-Akt Western 4691S Cell Signaling Technology 
p-Akt Western 4060S Cell Signaling Technology 
Zeb1 Western sc-515797 Santa Cruz 
Twist Western sc-81417 Santa Cruz 
Actin Western A2066 Sigma-Aldrich 
Gt-α-rb IgG HRP 
conjugate 
Western 12-348 Millipore 
 
Table 3.3 Primers for RT-qPCR 
Primer Forward Reverse 




TGFβ CGCAACAACGCCATCTATGA ACCAAGGTAACGCCAGGAAT 
N-Cadherin GGGACAGGAACACTGCAAAT CGGTTGATGGTCCAGTTTCT 
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Vimentin ATGCTTCTCTGGCACGTCTT AGCCACGCTTTCATACTGCT 
MMP2 ACACTGGGACCTGTCACTCC GCGAAGAACACAGCCTTCTC 
MMP9 CATTCGCGTGGATAAGGAGT ACCTGGTTCACCTCATGGTC 
Fibronectin TTAAGCTCACATGCCAGTGC TCGTCATAGCACGTTGCTTC 
Cortactin GCCACTATCAAGCAGAGG CCAGCCATCGTCAATCAT 
Tks5 AGGAGGCTGAGGAGAATC ATGCTTGTCACCTGAACC 


























Figure 3.1 Adjuvant emodin treatment decreases metastatic recurrence of TNBC 
after surgical resection. A, Timeline of this experiment. 7 week-old, female BALB/c 
mice received 2x105 4T1-luc2 cells in the 4th right (9th) mammary fat pad. Tumors were 
resected as indicated on the timeline, and treatment with either 2% DMSO in PBS 
(vehicle), 20 mg/kg emodin, or 40 mg/kg emodin was administered i.p. daily for the 
duration of the study beginning on the same day that tumors were resected. B, IVIS 
image of tumors prior to resection. C, IVIS image of mice immediately following tumor 
resection. D, Tumor weight at resection, tumor radiance from IVIS image in B, and tumor 
growth until resection; no differences between groups are apparent. E, Day 24 and Day 
30 lung field radiance from IVIS imaging and Day 38 IVIS radiance from lungs imaged 
ex vivo. F, IVIS image from Day 30 showing lung metastases in multiple mice. G, Ex 
vivo lung IVIS image on Day 38. H, Representative lung sections with metastases 
identified. I, Quantification of lung metastases from serial sections. J, Prevalence of gross 
lung metastases from IVIS data at the conclusion of the experiment. Results are shown as 















Figure 3.2 Emodin modulates the immune microenvironment of the metastatic site. 
A, Representative flow cytometry result and quantification of Tregs in lung-draining 
lymph nodes. B, Representative flow cytometry result and quantification of migratory 
DCs in lung-draining lymph nodes. C, Quantification and representative 
immunofluorescence staining of Ym1+ cells in lung metastases; scale bar = 50 µm. D, 
Ym1 staining showing M2 macrophages aggregating in the peripheral area of the lung 
metastases; scale bar = 100 µm. E, Quantification of activated CD8+ T cells in lung-
draining lymph nodes from flow cytometry. Results are shown as means ± SE (n=13-14). 














Figure 3.3 Emodin inhibits breast tumor cell EMT through modulating macrophage 
phenotype and TGFβ secretion. A, qPCR of TGF-β1 in macrophages treated with 
EO771-conditioned medium, emodin (25 µM), or both. B, ELISA for TGF-β1 in 
supernatants from macrophages treated as in A. C, Non-contact macrophage/tumor cell 
co-culture schematic. D, qPCR of 4T1 cells after 24 h of non-contact co-culture with 
macrophages pretreated as shown for EMT-related genes. E, qPCR of EO771 cells after 
24 h of non-contact co-culture with macrophages pretreated as shown for EMT-related 

















Figure 3.4 Emodin inhibits TGF-β and tumor-associated macrophage-induced 
migration and invasion of tumor cells. A, Representative images of 4T1 cell migration 
during treatment with TGF-β1 (5 ng/mL), emodin (25 µM), or both. B, Quantification of 
4T1 and MDA-MB-231 cell migration when treated as in A. Migration index = (width 
before migration-width after migration)/width before migration, normalized to vehicle 
control (DMSO). C, Representative images of 4T1 cell migration during treatment with 
conditioned medium from macrophages pretreated as shown. D, Quantification of 4T1 
cell migration treated as in C. E, Representative images of 4T1 cell Matrigel® invasion 
during treatment with TGF-β1 (5 ng/mL), emodin (25 µM), or both. F, Quantification of 
4T1 and MDA-MB-231 cell migration treated as in E. G, Representative images of 4T1 
cell Matrigel® invasion during treatment with conditioned medium from macrophages 
pretreated as shown. H, Quantification of G. I, qPCR of invadopodia-related genes from 
EO771 tumor cells treated with conditioned media from macrophages pretreated as 































Figure 3.5 Emodin interferes with both TGF-β canonical and non-canonical 
signaling in tumor cells. 4T1(A), EO771 (B), and MDA-MB-231 cells (C) were treated 
with TGF-β1 (5 ng/mL) with or without emodin (25 µM) for 1 h; Smad2/3 and p-
Smad2/3 protein levels were detected by western blot. D, 4T1 cells were treated as in A-
C; protein levels of STAT3, p-STAT3, Akt, and p-Akt were detected by western blot. E, 
4T1 cells were treated with TGF-β1 (5 ng/mL) with or without emodin (25 µM) for 24 h; 
protein levels of Twist and Zeb1 were detected by western blot. Results are shown as 





GENERATION OF A MICRORNA-155 TRANSGENIC MOUSE MODEL 
4.1 BACKGROUND 
MicroRNA-155 (miR155) is processed into its active form from its primary 
transcript, the B cell Integration Cluster (BIC), located on chromosome 21 in humans 
[149]. BIC is so named due to its initial discovery as a transcript present in chicken B cell 
lymphomas induced by integration of the avian leukosis virus [150]. Sometime later it 
was appreciated that pre-miR155 was transcribed from the BIC region in chickens and 
was similarly expressed in humans. In fact, miR155 is highly conserved between species 
and orthologs have been identified in many species including the evolutionarily ancient 
Ciona intestinalis. This early appearance and relatively unaltered maintenance of miR155 
in the evolutionary tree also seem to coincide with the development of innate and 
adaptive immunity. C. intestinalis possesses a complex innate immune system and some 
degree of adaptive immunity through antigen receptor rearrangement [151, 152]. Tied to 
this and the initial discovery of the BIC locus in relation to abnormal, virally-induced B 
cell expansion, a number of studies have demonstrated the importance of miR155 for 
many immune processes and for antitumor immunity, specifically, in several cell types 
[153]. BIC, and subsequently miR155, overexpression has been observed in human 
Hodgkin’s and diffuse large B cell lymphomas [154-157]. Transgenic mice, engineered 
to overexpress miR155 specifically in B cells, exhibit abnormally enhanced pre-B cell 
proliferation which develops into B cell lymphoma [158]. It is not clear where enhanced 
95 
 
miR155 expression falls in the pathogenesis of human B cell lymphomas, but this murine 
study at least lends some credence to the possibility of a causative relationship. In 
addition to mounting evidence demonstrating a connection between B cell development 
and proliferation and miR155, it has also been shown that miR155 deficiency in B cells 
reduced both IgM and IgG antibody production in response to Salmonella infection [159, 
160]. In addition to this finding, other studies have shown decreased number and size of 
lymph node germinal centers in miR155-deficient mice [161-163].   
miR155 transcription is physiologically induced in both B and T cell activation 
[157, 164, 165]. There have been many studies detailing mechanisms of miR155 activity 
in T cell populations. Tumor-infiltrating CD8+ and CD4+ T cells have been shown to 
require miR155 for proper IFNγ expression and tumoricidal activity [166]. 
Overexpression of miR155 in CD4+ T cells has also been shown to promote in vitro Th1 
cell differentiation [167], but proliferation was not found to be different between wild-
type and miR155-deficient CD4+ T cells in an in vivo murine model of antigen-dependent 
T cell activation [160]. Notably, miR155 can directly target SOCS1, a JAK/STAT 
inhibitor, Ptpn2, a STAT5 inhibitor, and SHIP1, a PI3K/AKT inhibitor, thus increasing 
the activity of these three pathways [168-170]. Due to these regulatory pathways, 
increased T cell miR155 expression led to enhanced T cell survival and antitumor activity 
in murine models of melanoma. The role of miR155 in Tregs has been shown to involve 
similar pathways, but to a different immunologic effect. It was observed that miR155 was 
inhibited by the STAT5 pathway in response to CD69 deficiency, which in turn ked to 
increased SOCS1 expression and impairment of Treg development [171]. Interestingly 
this study places STAT5 upstream of miR155 in Tregs, while the previously described 
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studies place it downstream [168-170]. It may be the case that both of these relationships 
are present simultaneously in both cell types, creating a negative feedback loop on 
miR155 activity. Other studies have also reported Treg dependence on miR155 
expression for proliferative capacity, but also that the miR155-dependent reduction in 
total Treg burden did not correspond to a measurable decrease in their immune 
suppressive activity [172, 173]. All of the studies described thus far were performed in 
mice, but it has also been found that miR155 in human dermal lymphatic endothelial cells 
(HDLECs) suppresses PD-L1 expression induced by TNFα and IFNγ [174]. Indeed 
miR155 is also the most highly up-regulated microRNA in HDLECs responding to TNFα 
and IFNγ; in this case, naturally dampening the increase in PD-L1 expression [174].  
In cells of monocytic lineage, miR155 has been shown to play both positive and 
negative roles in controlling the mammalian immune response [165, 175-177]. The 
immunosuppressive functions of myeloid-derived suppressor cells (MDSCs) have been 
shown to be both increased and decreased by miR155 in murine models of lung cancer 
and melanoma[178, 179]. miR155 signaling has also been implicated in the activities of 
monocytes, macrophages, and DCs [180-183]. Direct targeting of arginase-2 (Arg2) by 
miR155 in DCs has been linked to increasing the extracellular availability of arginase, 
facilitating proper DC-induced T cell activation [184]. Our lab and others have 
previously shown that miR155 is a key regulator of DC function, and that its decreased 
expression in DCs leads to decreased migration and chemotaxis as well as generalized 
depression of maturation and subsequent T cell activation [7, 184-186]. Our studies 
uncovered a correlation between CCR7 expression, important for DC migration, and 
miR155 in a murine orthotopic breast tumor model. We demonstrated that a potential 
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mechanism for miR155’s regulation of CCR7 expression is through directly targeting 
Jarid2, which in turn recruits PRC2, a component protein of a complex with histone 
methyltransferase activity. PRC2 represses genes primarily by trimethlyating histone H3 
at lysine 27 (H3K27me3), and we found enriched H3K27 at the CCR7 promoter in 
miR155-/- BMDCs [105]. Unsurprisingly, SHIP1, also shown to be an important target of 
miR155 in T cells, has been revealed to be similarly influenced in DCs. In a model of 
DC-induced autoimmunity, miR155-/- DCs pulsed with self-antigen and matured with 
toll-like receptor (TLR) ligands ex vivo did not bring about a break in self-tolerance, 
while wild-type DCs treated in the same manner did, and DCs overexpressing miR155 
did so even without TLR-ligand assisted maturation. SHIP1 expression was increased in 
miR155-/- DCs, and SHIP1 knockout in DCs allowed for the induction of autoimmunity 
in the absence of TLR ligand stimulation, similar to what was achieved with miR155-
overexpressed DCs [187]. Studies of human DCs differentiated from peripheral blood 
monocytes have also focused on the role of miR155. IL-12p70 has been shown to 
correlate with miR155 expression level, and maturation of monocyte-derived DCs has 
been associated with increased miR155 expression [173, 185].  
Only one of these studies used a transgenic miR155 overexpression model [187]. 
The miR155-transgenic mice in this study were generated by crossing mice containing a 
Rosa26 knock-in of the miR155/bic gene preceded by a stop codon with mice expressing 
Cre recombinase under the control of the CD11c promoter. Generating transgenic mice 
using this method requires continued crossing and genotyping to verify that both the 
transgene and Cre recombinase are expressed in the same mouse. Given that these mice 
were used to generate bone marrow-derived dendritic cells and not directly for in vivo 
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experiments, this CD11c specificity does not seem necessary. Our model globally 
overexpresses miR155 at a stable level, therefore removing the additional steps of 
crossing and genotyping when generating BMDCs for in vitro studies or adoptive 
transfer.  
However, the majority of studies seeking to investigate the effects of increased 
miR155 expression achieve this by viral transfection. DCs are notoriously difficult to 
successfully transfect, and successful infection rates are often low [188]. To reliably 
study the effects of augmented miR155 expression, a stable, transgenic overexpression 
model could prove very useful. We have developed and validated such a model and 
demonstrated the effects of total immune system miR155 overexpression in a murine 
orthotopic breast tumor model. Detection of the presence of the transgene as well as 
increased expression of mature miR155 in bone marrow, bone marrow-derived DCs 
(BMDCs), peritoneal macrophages, and genotyping tail clips confirm that the transgene 
is actively transcribed and processed. Transplantation of miR155 transgenic (miR155tg) 
bone marrow into wild-type mice later implanted with breast tumor cells confirmed that 
the net effect of increased global immune system miR155 leads to more effective 
antitumor immunity and prevention of metastatic dissemination.  
4.2 DETAILED METHODS 
Generation and validation of a miR155 transgenic mouse model  
A DNA fragment consisting of a CMV promoter, the mouse Bic sequence, and a 
SV40 late polyadenylation signal sequence was used for generation of miR155 transgenic 
mice by microinjection. Of the 90 pups implanted with the DNA fragment, four were 
found to be positive for the transgene following PCR screening. qPCR of tail clips from 
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these four mice further showed that only one of them was obviously producing mature 
miR155. Every pup from this single founder’s line was genotyped using PCR and 
assessed for overexpression of mature miR155 using qPCR until six generations of mice 
were produced.  
Genotyping PCR 
 3 mm tail clips were obtained from 4 week-old pups. 6 wild-type tail clips were 
also obtained as age-matched controls for genotyping and qPCR; 3 male, 3 female. Half 
of each piece of tissue was used for end-point PCR genotyping and half was used for 
qPCR. Tail clips were incubated in 150 µL DirectPCR (Tail) solution (Viagen Biotech 
Inc., Los Angeles, CA) containing 2 µL Proteinase K (Viagen Biotech Inc.) at 55˚C in a 
shaking water bath overnight. The digestion was terminated by 1 h incubation at 85˚C. 
Resulting lysate was then centrifuged at 17,000 x g for 1 min. 3 µL of the supernatant 
was taken and mixed with 10 µL 2X green master mix (Promega Corp., Madison, WI), 
0.1 µL of both the forward and reverse primer, and 6.8 µL of water to bring the final 
reaction volume to 20 µL. PCR amplification was done as follows: 5 min at 94˚C 
followed by 36 cycles of 30 s at 94˚C for denaturation, 1 min at 60˚C for annealing, and 1 
min at 72˚C for extension. The last cycle was followed by 3 min at 72˚C additional 
extension. Primers are listed in table 4.1. 10 µL of each resulting solution and a 100 bp 
ladder (Bioline, London, England) were loaded into separate wells of a 1% agarose gel 
containing 6 µL ethidium bromide per gram agarose and run for 50 min at 120V, after 
which the gel was imaged using a GelDoc XR+ Imaging System (Bio-Rad Laboratories) 




Total RNA extraction and quantitative real-time PCR 
 Tissue/cells were lysed in 700 µL qiazol lysis reagent (Qiagen) and tissue samples 
were homogenized. Samples were stored at -80˚C if RNA extraction was not performed 
immediately. RNA was extracted using miRNeasy Mini Kits (Qiagen) to also ensure 
collection of micro-RNAs. cDNA was then synthesized using 1 µg RNA, or the 
maximum amount possible if less than 1 µg, using miScript II RT Kits (Qiagen). RNA 
concentration was measured using an Evolution 60 spectrophotometer (Thermo Fisher 
Scientific). qPCR was performed using miScript SYBR® Green PCR Kits (Qiagen). All 
cDNA stocks were diluted 1:50, and 2 µL of the resulting solution was used for each 
qPCR reaction. Primers are listed in table 4.1. qPCR run conditions were 95˚C for 15 min 
followed by a repeated cycling of 94˚C for 15 s, 55˚C for 30 s, and 70˚C for 30 s. A melt 
curve was then collected through the following temperature fluctuations: 95˚C for 10 s, 
65˚C for 5 s, and terminating again at 95˚C.  All samples were run in duplicate using a 
Bio-Rad CFX Real Time thermocycler. The ΔΔCt method was used to determine relative 
expression.  
Peritoneal macrophage collection 
 Brewer’s thioglycollate was prepared at a concentration of 4% and injected i.p. 
into mice at a volume of 100 µL per gram mouse weight. Three days after thioglycollate 
injection mice were sacrificed and macrophages were obtained by peritoneal lavage with 
20 mL PBS. Cells were resuspended and plated in DMEM 10% FBS P/S, cultured for 1 
h. Non-adherent cells were then rinsed away with serum-free DMEM; adherent cells 
were cultured overnight in serum-free DMEM before being rinsed twice with PBS and 
lysed for RNA extraction and qPCR.  
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Bone marrow derived dendritic cell differentiation 
 4-12 week old mice (wild-type C57Bl/6 or miR155tg) were anaesthetized with 
isoflurane and sacrificed by cervical dislocation. Hind legs were removed, dipped in 70% 
ethanol, and placed in PBS on ice. Femurs and tibiae were cleaned and disarticulated in a 
cell culture hood on ice. Epiphyses were removed from diaphyses and rinsed with 
complete RPMI (RPMI-1640, 10% heat-inactivated FBS, P/S, and BME) to remove the 
bone marrow. Bone marrow was then resuspended in 1 mL RBC Lysing Buffer (Sigma-
Aldrich Corp.) per mouse and gently disrupted by pipetting for 1 min. Lysing buffer was 
then diluted with 20 mL RT PBS, centrifuged to pellet and resuspended in complete 
RPMI for counting. Bone marrow cells were plated in 10-cm tissue culture-treated, 
polystyrene dishes at a density of 3x106 cells/mL in 10 mL complete RPMI supplemented 
with 20 ng/mL recombinant murine GM-CSF (Peprotech, Rocky Hill, NJ) and 20 ng/mL 
recombinant murine IL-4 (Peprotech) (DC medium) and cultured at 37˚C, 5% CO2 
incubator. 10 mL additional DC medium was added on Day 3, and immature, 
differentiated DCs were collected on Day 7.  
Bone marrow transplantation 
6-week-old, female C57Bl/6 wild-type mice were purchased from Jackson Labs 
and housed at the University of South Carolina Animal Research Facility. Procedures 
were approved by the Institutional Animal Care and Use Committee. Mice were treated 
with Neomycin and polymyxin B, administered in drinking water at concentrations of 
100 mg/L and 5x105U/L, respectively, for two weeks prior to irradiation and bone 
marrow transplantation. Mice were exposed to a dose of 950 rad to ablate existing bone 
marrow cells. Donor bone marrow cells (wild-type or miR155tg) were prepared at a 
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concentration of 10x106 cells/mL in PBS by rinsing femurs and tibiae followed by RBC 
lysing buffer as described previously. 100 µL of appropriate genotype donor bone 
marrow cell suspension was injected retro-orbitally into each mouse 6 h after irradiation. 
Mice were then maintained on neomycin/polymyxin B-containing water for two 
additional weeks after bone marrow transplantation. At sacrifice bone marrow was 
collected from all mice and both end-point PCR and qPCR were performed as described 
previously to confirm that the transgene was present in the bone marrow and that miR155 
was overexpressed.  
Tumor model 
Four weeks after bone marrow transplantation, the recipient mice were inoculated 
with breast cancer cells. 0.2x106 EO771 cells were implanted into the 4th and 9th 
mammary fat pads. Tumors were measured using calipers every 3-5 days beginning on 
Day 14 when the majority of tumors were obviously palpable. Tumor volume was 
calculated using the following formula: (short axis)2 x (long axis)/2 ≈ volume. Mice were 
sacrificed 37 days after tumor implantation, and tumors, lungs, blood, spleens, and 
tumor-draining lymph nodes were collected.   
Lung metastatic burden determination 
Lungs were perfused with PBS, then fixed for 24 to 48 h in 10 mL 4% 
paraformaldehyde. Fixed lung were imbedded in paraffin and sectioned at 5 µm thickness 
at 150 µm intervals. 5 levels were obtained at this spacing from each pair of lungs. 
Sections were mounted, de-paraffinized, and H&E stained. Stained sections were then 
imaged at 10X magnification using an EVOS FL Auto 2 System (Thermo Fisher 
Scientific). Images were tiled in order to view the entire lung using the EVOS System 
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software. Size of images were limited such that they did not require compression to be 
saved by the EVOS System software, ensuring that pixels represented equivalent real 
dimensions on every section. Pixel areas of lung tissue and metastases were measured for 
each image by hand using ImageJ software. These pixel values were converted to mm2 
using the conversion factor 1.142 pixels/µm determined by the 10X objective. The 
number of metastatic nodules per section was also counted. These values were used to 
calculate the following parameters for each lung pair: 1) metastatic burden = (metastatic 
volume)/(total lung volume), 2) (number of metastases per section)/(lung section area).   
Flow cytometry 
Tumor tissue, spleens, and tumor-draining lymph nodes were collected from mice 
and single cell suspensions of these tissues were analyzed using flow cytometry. Tumors 
were chopped into <1 mm3 fragments and enzymatically digested in the following 
mixture: 20 mg Collagenase IV (Worthington Biochemical Corp.), 10 µg Hyaluronidase 
(Sigma-Aldrich Corp.), and 100 µg DNase 1 (Sigma-Aldrich Corp.) in 5 mL RPMI-1640 
medium supplemented with P/S. Digestion took place in a 37˚C water bath for 1 h during. 
During this time, the mixture was agitated every 15 min by pipetting or vigorous shaking. 
The mixture was then further disrupted using an 18 gauge needle and 10-mL syringe until 
most visible fragments were broken up. The mixture was then placed back at 37˚C for 15 
more min of digestion. After this final incubation, add 20 mL RT or ice-cold PBS to each 
tube to stop digestion. Cells were thoroughly rinsed to remove all digestion enzyme. Red 
blood cells were lysed using RBC lysing buffer (Sigma-Aldrich Corp.), 3 mL for 1 min at 
RT with gentle pipetting. This was then diluted with 20 mL PBS and passed through a 
70-µm strainer, then suspended in PBS and counted. Lymph nodes and spleens were 
104 
 
mechanically dissociated and passed through a 70-µm strainer. Spleen cells were then 
treated with 1 mL RBC lysing buffer for 1 min at RT with gentle pipetting. Both 
splenocytes and lymphocytes were then rinsed, resuspended in PBS and counted. Blood 
was collected in 1.5 mL Eppendorf tubes containing 12 µL of 0.5-M EDTA to prevent 
clotting. 100 µL of each blood sample was collected for treatment with 1 mL RBC lysing 
buffer as described previously, rinsed with PBS and counted.   
 Fc receptors were blocked with anti-CD16/32 antibodies (BD Biosciences, San 
Jose, CA) for 10 min at 4˚C. Cells from the various tissues collected were then stained for 
the following surface markers: CD45, CD3, CD4, CD8, CD11c, MHCII, CD40, CD80, 
CD86, CCR7, CD11b, Ly6C, and CXCL1 (BD Biosciences, San Jose, CA) in 100 µL 
PBS for 30 min at 4˚C. Internal staining was performed for IFNγ (BD Biosciences) using 
eBioscience Cell Stimulation Cocktail (Thermo Fisher Scientific) followed by BD 
fixation and permeabilization treatment per manufacturer protocols. All samples were 
rinsed with PBS twice before being analyzed using a BD FACS Aria II flow cytometer 
and CXP software version 2.2 (BD Biosciences). Data were collected for 1x104 to 1x106 
cells per sample depending on the rarity of the population being analyzed.  
Statistical analysis 
Data were shown as mean ± standard error of mean (SEM) whenever the mean 
was the primary value representative of a sample group’s behavior. Two group 
comparison of means was accomplished using a 2-tailed Student’s t test. All such 
comparisons were performed using GraphPad Prism 5 software (Graphpad Software 





The miR155-containing transgene is present, expressed, and functional in one founder 
Previous studies in our lab have shown that total body miR155-/- increased breast 
tumor growth and metastasis, largely though hampering the immune stimulatory abilities 
of DCs [105]. Administration of a miR155-/- DC-based vaccine was also carried out in an 
orthotopic model of murine breast cancer, which was less effective that a wild-type DC-
based vaccine at stimulating an antitumor immune response. We next aim to investigate 
whether increasing immune cell miR155 expression could represent a potential 
therapeutic strategy for breast cancer, setting the stage for possible future testing of a 
miR155-overexpressed DC-based vaccine. In order to produce a model stably 
overexpressing miR155, whole-body transgenic mice were generated. The transgene we 
designed is under the control of the cytomegalovirus (CMV) promoter for constitutive 
expression, though the microRNA will likely be processed into its active form to varying 
degrees in different cell populations. Four founder mice (3 male, 1 female) successfully 
integrated the transgene into their DNA. Through qPCR on tissue samples from these 
founders as well as transgene-positive offspring, it was determined that only one of the 
male founders functionally overexpressed miR155, so this line was bred and expanded. 
All transgene-positive offspring from this line were found to overexpress miR155 
(Figure 4.1A). One of the transgene-positive F1 mice was sacrificed; peritoneal 
macrophages and bone marrow-derived DCs were obtained from this mouse as well as an 
age and gender-matched C57BL/6 wild-type control mouse (Figure 4.1B-D). It was 
revealed that miR155 was also overexpressed in these two immune cell types, and, 
unsurprisingly, that baseline miR155 expression was higher in both of these cell types 
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than it was in the ear tissue obtained for genotyping. The expression levels of a few other 
genes were also determined in order to more convincingly establish that more functional 
miR155 was indeed present in the transgenic DCs. SOCS1 and CEBPβ are known to be 
direct targets of miR155, and thus their expression levels should be reduced in the 
miR155tg cells. Our previous work detailed a regulatory pathway by which CCR7 
expression is indirectly increased by miR155, thus it would be expected to be more 
highly expressed in the miR155tg DCs. These three genes do appear to reflect a pattern 
indicative of the effect of increased functional miR155 (Figure 4.1E). These results 
suggest that our model would yield stable, functional miR155 overexpression in immune 
cells that could be used in subsequent studies.  
Bone marrow cell miR155 overexpression reduces breast tumor growth and lung 
metastatic burden 
In order to further test both the stable presence and the effects of transgenic 
overexpression of miR155, a bone marrow transplant study was performed. There is an 
ever-increasing body of work demonstrating that manipulation of miR155 expression 
levels leads to altered activity in many immune cell populations. Our previous work using 
whole-body miR155-/- mice showed that miR155 was important for a number of 
pathways governing the antitumor immune response in DCs, which led to increased 
breast tumor growth and progression. Bone marrow transplantation using either C57BL/6 
wild-type or miR155tg donor tissue and wild type recipients was performed and mice 
were allowed four weeks after transplantation for immune system reconstitution before 
orthotopic implantation of EO771 tumor cells. This resulted in reduced EO771 tumor 
growth and tumor weight at sacrifice after 35 days of tumor growth (Figure 4.2B). There 
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was little difference between the average spleen weights between the two groups (Figure 
4.2C). However, it was found that both spleens and tumor-draining lymph nodes 
contained significantly more cells in the miR155tg bone marrow transplant recipient 
(BM-miR155tg) mice (Figure 4.2D). These data suggest that there was likely a more 
robust antitumor immune response in the BM-miR155tg mice, both locally and, to some 
degree, systemically. The final gross phenotypic observation in this study was the 
difference in metastatic dissemination. Lung metastases were drastically reduced in 
overall burden (metastasis index = metastasis volume/total lung volume) (Figure 4.2E). 
The average number of metastases was lower, but did not reach statistical significance, 
though the average size of each metastasis was decreased in the BM-miR155tg recipient 
mice (Figure 4.2E). Taken together, these results indicate that bone marrow miR155 
overexpression resulted in a stronger antitumor immune response against orthotopic 
breast tumors.  
Further analysis of the immune response in the tumor microenvironment as well 
as in other tissues relevant to the development of local and systemic antitumor immunity 
is necessary to determine the impact of bone marrow-derived cell miR155 
overexpression. Bone marrow was also collected from the right femur and tibia of every 
mouse in this experiment in order to roughly determine the efficacy of the transplant. 
qPCR showed that miR155 expression was on average ~10-fold higher in the 
miR155tgBMT mice than those that received wild-type bone marrow, though there was 
some variability (Figure 4.2F). Interestingly, though the number of bone marrow cells 
collected from each mouse was not counted, we found that the total amount of mRNA 
collected from the BM-miR155tg mice bone marrow was significantly higher than that of 
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the BM-wild-type mice (Figure 4.2G). This most likely indicates that more bone marrow 
cells were present in the BM-miR155tg mice, though the same number of cells were 
originally transplanted into each mouse. It is likely that the miR155 imparts some 
increased proliferative capacity to these progenitor cells [189].  
Bone marrow cell miR155 overexpression increases dendritic cell frequency, maturation, 
and T cell activation in tumor tissue and tumor draining lymph nodes 
Based on results previously reported by our lab and others, the observed 
differences in EO771 tumor progression between BM-miR155tg and BM-wild-type mice 
may be due to the activities of any number of immune cell populations. Our previous 
studies using total body miR155-/- mice indicated that, of the immune cell types analyzed 
in tumor draining lymph nodes (B cells, T cells, macrophages, and DCs), DCs were most 
significantly decreased in number, and likely contribute to the observed T and B cell 
deficits in addition to the miR155-/- in both of these cell types. In order to generate a more 
complete picture of the role of miR155 in the immune response to breast cancer, we 
investigated several immune cell populations in the tumors, tumor-draining lymph nodes, 
spleens, and blood of BM-miR155tg and BM-wild-type mice. These tissues were chosen 
to collectively represent both systemic and local tumor immunity, and determine the 
effect of miR155 overexpression on the balance between antitumor immunity and tumor-
induced immune suppression.  
In the blood, it was found that there was no difference in total T cell percentage, 
but there were more CD8+ T cells and less CD4+ T cells in the BM-miR155tg mice 
(Figure 4.3A). CD69 staining was used to determine the activation of circulating T cells. 
Interestingly, there were no differences in the percentages of CD69+ cells among either 
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the CD4+ or CD8+ T cells, though as a percentage of total circulating T cells, there were 
more CD8+CD69+ and less CD4+CD69+ cells in the BM-miR155tg mice due to the 
aforementioned differences in CD4+ and CD8+ T cell populations (Figure 4.3B). The 
percentage of Ly6C+ blood monocytes was not different between the two groups, and 
neither was the overall presence of CX3CR1 or CCR2 on these Ly6C+ monocytes 
different between the two groups Figure 4.3C). These markers have been shown to 
identify monocytes preferentially infiltrating non-inflamed and inflamed sites, 
respectively [190-192].  
Spleen tissue was mechanically dissociated and processed for flow cytometry. 
When total numbers of cells were considered, there were more CD11c+ DCs present in 
the spleens of BM-miR155tg mice (Figure 4.3D). Of the maturation markers MHCII, 
CD40, CD80, and CD86, all exhibited slightly higher expression on the splenic DCs of 
the BM-miR155tg mice (Figure 4.3E). The overall percentages of T and B cells 
(identified using CD3 and CD19, respectively) were not different between the BM-
miR155tg and BM-wild-type mice, but the percentage of splenic CD8+ T cells also 
expressing IFNγ was significantly higher in the miR155tgBMT mice (Figure 4.3F&G). 
Taken together, these blood and spleen flow cytometry data indicate that there is a mild 
systemic increase in cytotoxic adaptive immunity. The splenic DCs, while present in 
greater numbers, do not appear to be drastically more activated in the BM-miR155tg 
mice. The examination of relative B cell burden was meant to address concerns that 
miR155 has been observed to be overexpressed in B cell lymphomas and is thought to be 
causative in some cases. In fact, B cell-specific miR155 overexpression in mice has been 
observed to result in B cell lymphoma formation, though we observed no aberrant 
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relative expansion of B cells when miR155 was overexpressed in our bone marrow 
transplant model. This could be due to the adult bone marrow contributing more to 
myeloid than lymphoid populations.  
Tumor draining lymph nodes were also analyzed by flow cytometry and were 
found to contain many more CD11c+ DCs in the BM-miR155tg mice, and these DCs also 
expressed much higher levels of the maturation marker CD80. CD40, MHCII, and CD86 
expression was not found to be significantly different between the two groups (Figure 
4.3H&I). CCR7 expression was found to be much higher on the BM-miR155tg lymph 
node DCs, a result supportive of our previous finding that miR155 indirectly upregulates 
CCR7 transcription in DCs (Figure 4.3J). BM-miR155tg mouse lymph nodes also 
contained slightly more CD8+ T cells, but many more of these cells expressed IFNγ than 
those of BM-wild-type mice (Figure 4.3K).  
Primary tumors in BM-miR155tg mice were found to contain more CD11c+ DCs 
which also expressed more MHCII, CD80, and CD86 than tumor DCs from BM-wild-
type mice (Figure 4.3L&M). Also the DCs in the BM-miR155tg group’s tumors again 
expressed more CCR7 than those of BM-wild-type mice (Figure 4.3N). Interestingly, 
significantly more macrophages (F4/80+ cells) were present in the tumors of BM-
miR155tg mice, but these macrophages expressed less CD206, a marker of tumor-
promoting M2-like macrophages (Figure 4.3O). Macrophage populations were not 
analyzed in any of the other tissues, but these data appear to demonstrate that miR155 
may also affect macrophage polarization and the innate antitumor immune response. 
Though with only this one piece of data, we cannot be sure if this is a direct effect of 
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elevated miR155 expression in the macrophages, or an indirect effect brought about by 
the other alterations observed in the tumor microenvironment.  
4.4 DISCUSSION 
 Previous work by our lab and others has pointed to an immune stimulatory role 
for miR155, and several studies have been performed using knockout, knockdown, and 
cell-specific overexpression models to demonstrate this. However, our current study is 
the first time that a total-body miR155 overexpression model has been generated. The 
plan for this model is to generate DCs that constitutively express higher levels of miR155 
and to test their function compared to wild-type cells in response to the breast tumor 
microenvironment, but it is possible that this mouse model can be used to investigate the 
effects of constitutive miR155 overexpression in other immune cell types and tissues. 
When generating a transgenic mouse it is important to not only determine the presence of 
the transgene in the genome, but to ensure that it is expressed to a relevant degree and 
that this expression occurs throughout the animal. Due to random insertion, successful 
integration of the transgene into a region that is not heavily repressed can be challenging 
and require a large number of attempts to insure the successful generation of a transgenic 
animal [193]. In order to produce a single transgenic founder, 90 pronuclei were injected 
with the transgene. We have also confirmed that the transgene is expressed in a variety of 
tissues and that this expression has been maintained over five generations. The miR155 
overexpression was also shown to regulate a sampling of genes, SOCS1, CEBPβ, and 
CCR7 in a pattern consistent with the literature in order to further confirm that the 
overexpressed microRNA was also able to carry out its biological functions. This allowed 
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us to proceed with using these mice for further studies with some degree of confidence 
that stable, constitutive overexpression of miR155 had been achieved.  
 The first study that we performed with these mice was transplantation of bone 
marrow from miR155tg mice into wild-type recipient mice, followed by EO771 breast 
tumor implantation. Based on previous work, this would likely affect multiple 
populations of immune cells into which these bone marrow progenitors would 
differentiate. Cellular components of adaptive as well as innate immunity were analyzed 
in a diverse group of tissues related to the antitumor immune response. Gross assessment 
of the progression of the cancer was also quantified. In the tumor, spleen, blood, and 
tumor-draining lymph nodes, the most strongly affected populations of cells were the 
DCs and CD8+ T cells. These two populations exhibited both increased activation and 
relative abundance in response to miR155 overexpression. This finding is consistent with 
a number of previously performed studies [105, 169]. Interestingly, in the tissues 
analyzed, there did not appear to be a relative expansion of B cells, pathological or 
otherwise, as had been observed by others in models of B cell-specific miR155 
overexpression. The development of B cell lymphoma was reported to progress as the 
mice aged. We have not observed this phenomenon in the miR155tg mouse line even at 
relatively advanced ages of greater than 18 months.  
 Increased DC and cytotoxic T cell activation, as well as the observed decrease in 
the pro-tumor tumor-associated macrophage (TAM) phenotype likely all play roles in the 
observed inhibition of primary tumor growth and metastatic dissemination in the BM-
miR155tg mice. The reduction in metastasis was particularly striking and is the more 
clinically relevant of the two measures of breast cancer progression monitored in this 
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experiment. Through these experiments we have generated and validated a murine model 
of global miR155 overexpression, and can now move forward with studies of specific 























Table 4.1 Antibodies for flow cytometry 
Antibody Product # Company 
CD45 (PE/Cy7) 103113 Biolegend 
CD3 (APC/Cy7) 100221 Biolegend 
CD4 (APC) 100411 Biolegend 
CD8 (FITC) 100803 Biolegend 
CD69 (PE) 104507 Biolegend 
Ly6C (PE) 128007 Biolegend 
CX3CR1 (FITC) 149019 Biolegend 
CCR2 (PE) 150609 Biolegend 
CD11c (APC) 117309 Biolegend 
CD11c (FITC) 117305 Biolegend 
I-A/I-E (APC/Cy7) 107627 Biolegend 
CD40 (PE) 124609 Biolegend 
CD80 (FITC) 104705 Biolegend 
CD86 (APC) 105011 Biolegend 
CD19 (PE) 152407 Biolegend 
IFNγ (PE) 505807 Biolegend 
CCR7 (PE) 120105 Biolegend 
F4/80 (PE) 123109 Biolegend 
CD206 (APC) 141707 Biolegend 
 
Table 4.2 Primers for RT-qPCR 
Primer Product # Company 
U6 MS00014000 Qiagen 
miR155 MS00001701 Qiagen 
Primer Forward Reverse 
18s CGCGTTTCTATTTTGTTGGT AGTCGGCATCGTTTATGGTC 
CCR7 GCTTCTGCCAAGATGAGGTC CCACGAAGCAGATGACAGAA 
SOCS1 TTAACCCGGTACTCCGTGAC GAGGTCTCCAGCCAGAAGTG 






Figure 4.1 The miR155-containing transgene is present, expressed, and functional in 
one founder line. A, miR155 qPCR results from 4 wild-type control and all F1 miR155tg 
mice from the viable line determined to carry the transgene; all mice were tested at 4 
weeks old. B-D, miR155 expression in ear tissue, macrophages, and DCs of 5 wild-type 
vs. one miR155tg mouse at 4 weeks of age. E, The differential expression of genes 
known to be influenced by miR155 between wild-type and miR155tg mice determined by 












Figure 4.2 Total immune system miR155 overexpression reduces breast tumor 
growth and lung metastatic burden. A, Timeline of this experiment. 7 week-old, female 
C57Bl/6 mice received oral antibiotics for 2 weeks both prior to and after irradiation and 
bone marrow transplantation with either wild-type or miR155tg bone marrow. 4 weeks 
after bone marrow transplant, 2x105 EO771 tumor cells were implanted into each of the 
4th pair of mammary fat pads. B, Tumor growth over 35 days and tumor weights at 
sacrifice. C, Spleen weights at sacrifice. D, Total cells in spleens and tumor-draining 
lymph nodes. E, Manual counting of lung surface metastases; lung metastatic index, 
number, and average size determined from serial lung sections. F, miR155 expression in 
bone marrow of all mice at the conclusion of the study to confirm successful bone 
marrow transplant. G, RNA quantities obtained from right femurs and tibiae of all mice. 














































Figure 4.3 Total immune system miR155 overexpression increases dendritic cell 
frequency, maturation, and T cell activation in tumor tissue and tumor draining 
lymph nodes. Blood cells were stained with CD3, CD8, CD4, CD69, Ly6C, CXC3CR1, 
and CCR2 antibodies and analyzed using flow cytometry. A, Total circulating T cells 
(CD3+) and relative percentages of CD4+ and CD8+ cells within this population. B, CD69 
expression on CD8+ and CD4+ T cells was used to identify activated T cells. C, 
Circulating monocytes were identified using Ly6C, and CXC3CR1+ and CCR2+ 
populations of monocytes were quantified. Spleen tissue was dissociated to a single-cell 
suspension; stained with CD11c, MHCII, CD40, CD80, CD86, CD19, CD3, CD8, and 
IFNγ antibodies; and analyzed using flow cytometry. D, Splenic DCs (CD11c+). E, 
Splenic DC maturation was determined by MHCII, CD40, CD80, and CD86 staining. F, 
Splenic B cells (CD19+). G, Total splenic T cells (CD3+) and active cytotoxic T cells 
(CD8+IFNγ+). Tumor-draining lymph nodes were dissociated to a single-cell suspension; 
stained with CD11c, MHCII, CD40, CD80, CD86, CCR7, CD3, CD8, and IFNγ 
antibodies; and analyzed using flow cytometry. H, Lymph node DCs (CD11c+). I, Lymph 
node DC maturation was determined by MHCII, CD40, CD80, and CD86 staining. J, 
CCR7 expression on DCs. K, Total lymph node T cells (CD3+) and active cytotoxic T 
cells (CD8+IFNγ+). Tumor tissue was digested to a single cell suspension; stained with 
CD11c, MHCII, CD40, CD80, CD86, CCR7, F4/80, and CD206 antibodies; and analyzed 
using flow cytometry. L, Tumor DCs (CD11c+). M, Tumor DC maturation was 
determined by MHCII, CD40, CD80, and CD86 staining. N, CCR7 expression on DCs. 
O, Total tumor macrophages (F4/80+), M2-like macrophages (F4/80+CD206hi). Results 






MIR155 OVEREXPRESSION BOOSTS DENDRITIC CELL VACCINE 
EFFICACY FOR BREAST CANCER 
5.1 BACKGROUND 
DCs take up, process and present antigen to adaptive immune cells to foster an 
effective tumoricidal response [194-196]. In fact they are considered the most effective 
antigen presenting cells (APCs) [197]. It is for this reason that DCs are considered a 
bridge between innate and adaptive immunity and are key to eliciting an effective T cell 
response [198]. However, the immunosuppressive tumor microenvironment often renders 
DCs dysfunctional [194, 199-202]. This is one of the most important mechanisms of 
tumor escape from immune surveillance [203-205]. Considerable effort has been put into 
developing therapies targeting or consisting of DCs to attempt to overcome or circumvent 
this immune suppression, respectively [206]. One of the strategies to circumvent this 
tumor-induced immune suppression is to take the patient’s own precursor cells, often 
peripheral blood monocytes, and generate DCs from these for ex vivo manipulation [207]. 
These cells are pulsed with tumor peptide, then often treated with activating agents such 
as TLR ligands or TNF-α to increase their immune stimulatory capacity [208]. This 
artificial maturation and antigen acquisition process helps to focus the DCs’ activity on 
the tumor while removing them from the immune suppressive environment of the tumor-
affected tissue. Clinical success of these vaccines, however, has been limited for a 
number of reasons, including the lack of appropriate antigens, treatment of only high 
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stage disease, and re-introduction of these DCs into an immune suppressive environment 
[209]. Further enhancement of antigen presentation through regulatory manipulation may 
prove to be clinically valuable and help to overcome the immune suppression of the 
environment into which the DCs are introduced.  
It is known that several targets of microRNA-155 are downregulated in order to 
facilitate adequate expression of MHCII and costimulatory molecules on DCs [184-186]. 
Our lab has identified microRNA-155 (miR155) as a key regulator of DC function 
through studies involving miR155-/- mice and virally-induced DC overexpression in 
orthotopic models of breast cancer [105]. These studies showed that a lack of miR155 
results in defective antigen presentation and dampened costimulatory molecule 
expression, and as a result, reduced T cell activation. It was also determined that miR155 
exhibits control over CCR7 expression by decreasing H3K27me3 at the CCR7 locus 
through direct targeting of Jarid2. In order to test the potential therapeutic ramifications 
of increased miR155 expression in DCs for breast cancer treatment, a robust model of 
miR155 transgenic overexpression was generated, and cells from these mice were used to 
demonstrate the effects of increasing DC miR155 expression on antitumor immunity in a 
murine model of breast cancer. The goals of this study were to investigate the phenotypic 
changes resulting from miR155 overexpression in DCs and to test the efficacy of a 
miR155-overexpressing DC vaccine for breast cancer.  
5.2 DETAILED METHODS 
Tumor cell culture, conditioned medium, and lysate collection 
EO771 tumor cells were expanded in high-glucose Dulbecco’s modified eagle 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL 
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penicillin (Sigma-Aldrich Corp.), and 100 µg/mL streptomycin (Sigma-Aldrich Corp.) in 
a 37˚C, humidified, 5% CO2 incubator. Tumor conditioned medium was collected by first 
expanding EO771 cells to 70% confluence for in T-75 bottles (Corning). Medium was 
then removed, plates were gently rinsed once with phosphate-buffered saline (PBS), and 
10 mL of serum-free DMEM containing penicillin and streptomycin (P/S) was added. 
Cells were cultured for 48 h in this medium, which was then collected, centrifuged at 350 
x g for 5 min to remove large cellular debris, and filtered through a 45-µm vacuum filter 
(Corning). This medium was then concentrated using 3000D molecular weight cutoff 
centrifuge concentrators (Merck Millipore, Burlington, MA) to 25X. Aliquots were 
stored at -80˚C for later use. To treat immature DCs, conditioned medium was diluted 1:5 
in fresh RPMI-1640 medium supplemented with 10% heat-inactivated FBS, 100 U/mL 
penicillin (Sigma-Aldrich Corp.), 100 µg/mL streptomycin (Sigma-Aldrich Corp.), and 
50 µM beta mercaptoethanol.  
Tumor cell lysate for DC antigen loading was obtained by culturing EO771 cells 
in 10 cm cell culture-treated plates to 70% confluency in DMEM+10% FBS+P/S. About 
30 plates of cells were processed for each batch of lysate. In preparation for lysate 
collection, plates were washed with PBS, then replenished with 10 mL serum-free 
DMEM and cultured for 48 h in a humidified, 5% CO2 atmosphere. At the end of this 
incubation period, EO771 cells were rinsed with PBS and removed from plates using 5 
mL of 3-mM EDTA in PBS for 10 min at RT. Cells were pelleted by centrifugation, 
rinsed with PBS, and again pelleted. The cell pellet was then subjected to four 
freeze/thaw cycles alternating from 5 min in liquid nitrogen to 15 min in a 37˚C water 
bath. After the final freeze/thaw cycle, the pellet was vigorously resuspended in 5 mL 
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PBS, then centrifuged at 1x104 g for 10 min to remove cell fragments. The supernatant 
was collected and protein concentration was determined using the Lowry method. Single-
use aliquots of known protein concentration were stored at -80˚C. This material was used 
as a source of soluble tumor antigen.  
Bone marrow-derived dendritic cell differentiation and antigen pulsing 
Entire hind limbs were removed from mice and dipped in 70% ethanol then 
placed in ice-cold PBS. Femurs and tibiae were cleaned on ice in a laminar flow hood. 
Sterile mortar and pestle (Thermo Fisher Scientific) were used to crush bones in 4 mL 
RPMI-1640 medium+10% heat-inactivated FBS+P/S+BME (complete RPMI). Crushed 
bone fragments were rinsed with complete RPMI until all bone marrow was removed and 
collected. Bone marrow was depleted of erythrocytes using 1 mL red blood cell lysing 
buffer (Sigma-Aldrich Corp.) for 1 min with gentle pipetting at RT. The resulting cells 
were counted and cultured in 10cm cell culture-treated dishes at a density of 1x106 
cells/mL (10 mL per dish) in complete RPMI supplemented with 20 ng/mL recombinant 
GM-CSF (rGM-CSF) and 20 ng/mL rIL-4 (Peprotech) in a 37˚C, humidified incubator. 
10 mL fresh complete RPMI supplemented in the same way was added on Day 3 of 
culture. After eight days of culture, loosely adherent cells were collected by gentle 
pipetting. Cells were confirmed >80% CD11c+, >90% CD11b+, and <5% Gr1+. These 
resulting cells were suspended in either control or treatment medium at densities ranging 
from 0.2x106 cells/mL to 1x106 cells/mL for various experiments, then cultured for 48 h. 
Control medium consisted of complete RPMI+20% serum-free DMEM. Treatment 
medium was made up of complete RPMI+20% concentrated EO771-conditioned 
medium+100 µg/mL tumor lysate. After this tumor antigen pulsing treatment, DCs were 
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collected using 3-mM EDTA in PBS for 10 min at RT, washed, and used for various 
purposes.  
In vitro dendritic cell migration assay 
100 ng/mL CCL19 (Biolegend) in serum-free RPMI-1640 medium was added to 
24 well plates and allowed to equilibrate overnight in a 37˚C humidified, 5% CO2 
incubator. 0.2x106 control and tumor antigen-pulsed DCs were seeded into 8-µm pore 
size polystyrene trans-well inserts (Corning) in serum-free RPMI-1640 and allowed to 
migrate for 3 h at 37˚C. Trans-well inserts were then removed from these inserts and 
fixed in 4% paraformaldehyde for 20 min on ice. Cells on the upper surface of the inserts 
were wiped away with cotton swabs. Cells that had migrated to the underside of the insert 
were be stained with DAPI and counted. Each sample was run in triplicate, and 10 fields 
were collected at 10X magnification for each membrane using an EVOS FL Auto 2 
System. DAPI-stained cells were counted in each field using Image-Pro Plus analysis 
software (Media Cybernetics, Rockville, MD).  
In vivo dendritic cell migration assay 
Female C57BL/6 mice were housed at the University of South Carolina Animal 
Research Facility until they were 8 weeks old; all procedures were approved by the 
Institutional Animal Care and Use Committee. 0.2x106 EO771 tumor cells suspended in 
20 µL PBS were implanted into the 4th pair of mammary fat pads. The following day 
control and tumor antigen-pulsed DCs, treated as described, were stained with CFSE 
(Biolegend) per the manufacturer’s protocol and injected subcutaneously into the groins 
of tumor-bearing mice. 48 h later, mice were sacrificed, lymph nodes were removed and 
processed for flow cytometry to identify CFSE-labeled cells.  
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In vitro T cell activation and proliferation 
Day 8 bone marrow-derived DCs were plated in 24-well plates at a density of 
0.1x106 cells in 0.5 mL of either control or treatment medium and cultured for 48 h in a 
37˚C, 5% CO2, humidified incubator. T cells were obtained from the spleens of C57BL/6 
wild-type mice 12-20 weeks of age. This involved mechanical dissociation using a 
Seward Stomacher followed by passage through a 70-µm cell strainer (Corning) and 
treatment with 3 mL red blood cell lysing buffer for 1 min at RT. T cells were isolated 
from mixed splenocytes using EasySepTM Mouse T cell Isolation Kits (Stem Cell 
Technologies, Vancouver, Canada). Isolated T cells were then co-cultured with DCs to 
assess DC-induced naïve T cell activation and proliferation.  
 To assess DC-induced T cell activation, DCs were rinsed with PBS very gently 
twice to remove residual treatment medium, then 1-2x106 splenic naïve T cells were 
added in 1 mL complete RPMI-1640 medium. The co-culture was maintained in a 37˚C, 
5% CO2, humidified incubator for 48 h, then T cells were collected by rinsing the wells 
and stained to determine cell surface expression of CD69 on all T cells and intracellular 
expression of IFNγ on CD8+ T cells for flow cytometry.  
 T cell proliferation was determined by staining naïve splenic T cells with CFSE, 
then co-culturing these cells with matured DCs for 5 days in complete RPMI-1640 
medium supplemented with 20 U/mL recombinant mouse IL-2 (Biolegend). CFSE 
dilution through division was determined by flow cytometry. CFSE-stained samples of T 
cells alone and unstained T cells were used as representative negative and positive 




In vivo T cell activation 
7 week-old, female C57BL/6 mice were housed at the University of South 
Carolina Animal Research Facility; all procedures were approved by the Institutional 
Animal Care and Use Committee. At 8 weeks of age, 0.2x106 EO771 breast tumor cells 
were implanted into each of the 4th pair of mammary fat pads in all mice. 24 h after tumor 
implantation, EO771 tumor-conditioned medium and lysate-matured wild-type or 
miR155tg bone marrow-derived DCs were collected and 1x106 cells were injected 
subcutaneously into the groins of tumor-bearing mice (0.5x106 DCs injected into the left 
groin area, and the same for the right). A second DC injection was administered in the 
same manner four days later. Mice were sacrificed seven days after tumor cell 
implantation. Spleens and lymph nodes were collected and processed for flow cytometric 
analysis of T cell activation and a few other immunologically relevant parameters.  
Tumor model and dendritic cell vaccination 
Female C57BL/6 mice were purchased at 7 weeks of age (Jackson Labs) and 
housed at the University of South Carolina Animal Research Facility; all procedures were 
approved by the Institutional Animal Care and Use Committee. At 8 weeks old, 0.2x106 
EO771 breast tumor cells suspended in 20 µL PBS were implanted into the 4th pair of 
mammary fat pads in all mice. 24 h after tumor implantation, EO771 tumor-conditioned 
medium and lysate-matured wild-type or miR155tg bone marrow-derived DCs were 
removed from culture dishes by incubating in 3-mM EDTA for 10 min at RT. These DCs 
were then resuspended in PBS and 1x106 cells were injected subcutaneously into the 
groins of tumor-bearing mice (0.5x106 DCs injected into the left groin area, and the same 
for the right). This DC harvesting and injection procedure was repeated every three to 
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four days for a total of six DC injections. Tumor volume was monitored until sacrifice 
and was calculated according to the following formula: (short axis)2 x (long axis)/2 ≈ 
volume. Mice were sacrificed 38 days after tumor cell implantation (19 days after the 
final vaccine injection). Tumors, tumor-draining lymph nodes, spleens, and lungs were 
collected for various analyses.  
Flow cytometry 
Several tissues were collected and dissociated into single cell suspensions for 
flow cytometric analysis. Blood was collected in 1.5 mL Eppendorf tubes containing 10 
µL 0.5-M EDTA as an anticoagulant. 100 µL of this mixture was then treated with 3 mL 
red blood cell lysing buffer for 1 min at RT with gentle pipetting, rinsed counted, and 
1x106 cells were suspended in 100 µL PBS for staining. Blood cells were blocked with 
anti-CD16/32 antibodies as described and stained with the following markers for 30 min 
at 4˚C: anti-CD45 PE-Cy7, anti-CD3 APC-Cy7, anti-CD4 APC, anti-CD8 FITC, anti-
CD69 PE, anti-Ly6C APC, anti-CCR2 PE, and anti-CX3CR1 FITC.  
Spleens were mechanically dissociated using a Seward Stomacher in 10 mL 
RPMI-1640 medium supplemented with P/S. This mixture was then passed through a 70-
µm cell strainer (Corning) and treated for 1 min at RT with 3 mL red blood cell lysing 
buffer (Sigma-Aldrich Corp.), rinsed with PBS, counted, and 1x106 cells were suspended 
in 100 µL PBS for staining. Splenocytes were blocked with anti-CD16/32 antibodies as 
described and stained with the following markers for 30 min at 4˚C: anti-CD45 PE-Cy7, 
anti-CD11c APC, anti-CD11c FITC, anti-CD3 APC-Cy7, anti-CD19-APC, anti-CD4 
APC, anti-CD8 FITC, anti-IFNγ PE, anti-CD40 PE, anti-IA/IE(MHCII) APC-Cy7, anti-
CD80 FITC, anti-CD86 PE.  
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Lymph node cells were dissociated using 70-µm cell strainers (Corning), rinsed, 
counted, and 1x106 cells were suspended in 100 µL PBS for staining. Lymph node cells 
were blocked with anti-CD16/32 antibodies as described and surface stained with the 
following markers for 30 min at 4˚C: anti-CD45 PE-Cy7, anti-CD11c APC, anti-CD11c 
FITC, anti-CD3 APC-Cy7, anti-CD4 APC, anti-CD8 FITC, anti-CD69 PE, anti-CD40 
PE, anti-CD80 FITC, anti-CD86 PE, anti-IA/IE(MHCII) APC-Cy7, anti-CCR7 PE, anti-
F4/80 PE, and anti-CD206 APC.  Internal staining was performed using a BD 
Cytofix/Cytoperm Fixation Permeabilization Kit (BD Biosciences) according to the 
manufacturer’s instructions. The antibodies used to stain intracellular antigens were anti-
IFNγ PE and anti-FOXP3 PE, each at a concentration of 4 µg/mL in the specified buffer.  
Tumor tissue was chopped into <1 mm3 fragments and enzymatically digested in 
the following mixture: 20 mg Collagenase IV (Worthington Biochemical Corporation, 
Lakewood, NJ), 10 µg Hyaluronidase (Sigma-Aldrich Corp.), and 100 µg DNase 1 
(Sigma-Aldrich Corp.) in 5 mL RPMI-1640 medium supplemented with P/S. Digestion 
took place in a 37˚C water bath for 1 h during. During this time, the mixture was agitated 
every 15 min by pipetting or vigorous shaking. The mixture was then further disrupted 
using an 18 gage needle and 10 mL syringe until most visible fragments were broken up. 
The mixture was then placed back at 37˚C for 15 more min of digestion. After this final 
incubation, add 20 mL RT or ice-cold PBS to each tube to stop digestion. Cells were 
thoroughly rinsed to remove all digestion enzyme. Red blood cells were lysed using RBC 
lysing buffer (Sigma-Aldrich Corp.), 3 mL for 1 min at RT with gentle pipetting. This 
was then diluted with 20 mL PBS and passed through a 70-µm strainer, then suspended 
in PBS and counted. Lymph nodes and spleens were mechanically dissociated and passed 
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through a 70-µm strainer. Spleen cells were then treated with 1 mL RBC lysing buffer for 
1 min at RT with gentle pipetting. Both splenocytes and lymphocytes were then rinsed, 
resuspended in PBS and counted. Blood was collected in 1.5 mL Eppendorf tubes 
containing 12 µL 0.5-M EDTA to prevent clotting. 100 µL of each blood sample was 
collected for treatment with 1 mL RBC lysing buffer as described previously, rinsed with 
PBS and counted.    
All samples were washed twice with PBS after staining and resuspended in 500 
µL PBS for flow cytometry. Samples were analyzed on a BD FACS Aria II using FACS 
Diva software (BD Biosciences). 100,000 events were collected for each sample. All 
antibodies mentioned here were purchased from Biolegend.  
Total RNA extraction and quantitative real-time PCR 
Tissue/cells were lysed in 700 µL qiazol lysis reagent (Qiagen) and tissue samples 
were homogenized. Samples were stored at -80˚C if RNA extraction was not performed 
immediately. RNA was extracted using Qiagen miRNeasy Mini Kits to also ensure 
collection of micro-RNAs. cDNA was then synthesized using 1 µg RNA, or the 
maximum amount possible if less than 1 µg, using Qiagen miScript II RT kits. Primers 
are listed in table 5.1. qPCR run conditions were 95˚C for 15 min followed by a repeated 
cycling of 94˚C for 15 s, 55˚C for 30 sec, and 70˚C for 30 s. A melt curve was then 
collected through the following temperature fluctuations: 95˚C for 10 s, 65˚C for 5 s, and 
terminating again at 95˚C. All samples were run in duplicate using a Bio-Rad CFX Real 






Following PFA fixation for 24-48 h at RT, mouse lungs were paraffin imbedded 
and sections were cut 5 µm thick at 150 µm intervals. Five such sections were obtained 
for each lung pair. These were deparaffinized and stained with hematoxylin and eosin. 
Stained slides were imaged at 10X magnification using an EVOS FL Auto 2 System 
(Thermo Fisher Scientific). Images were tiled in order to view the entire lung using the 
EVOS System software. Size of images were limited such that they did not require 
compression to be saved by the EVOS System software, ensuring that pixels represented 
equivalent real dimensions on every section. Pixel areas of lung tissue and metastases 
were measured for each image by hand using ImageJ software. These pixel values were 
converted to mm2 using the conversion factor 1.142 pixels/µm determined by the 10X 
objective. The number of metastatic nodules per section was also counted. These values 
were used to calculate the following parameters for each lung pair: 1) metastatic burden = 
(metastatic volume)/(total lung volume), 2) (number of metastases per section)/(lung 
section area).  
Statistical analysis 
Data were shown as mean ± standard error of mean (SEM) whenever the mean 
was the primary value representative of a sample group’s behavior. Three group 
comparison of means is accomplished using a two tailed ANOVA followed by Tukey 
multiple comparisons test, while two group comparison was accomplished using a two 
tailed Student’s t test. All such comparisons are performed using GraphPad Prism 5 
software (Graphpad Software Inc.). Differences between proportions were determined 
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using a two tailed N-1 Chi-Square test. p≤0.05 was considered statistically significant for 
all tests.  
5.3 RESULTS 
Dendritic cell maturation is increased by miR155 overexpression 
DCs constantly sample their environments, take up antigen, and mature. This 
maturation process involves the up-regulation of MHCII, on which antigen is presented, 
as well as co-stimulatory molecules such as CD40, CD80, and CD86. Upon interaction 
with the corresponding stimulatory surface receptors of T cells, including CD40 ligand 
(CD154), T cell receptor, and CD28, T cell activation is induced. DC maturation is also 
accompanied by an increase in CCR7 expression, which enables DCs to respond to 
chemoattractant molecules such as CCL19 and CCL20 and migrate to draining lymph 
nodes where their chance of interacting with a receptive T cell is greater. Our previous 
results in miR155-/- mice showed that all of these molecules associated with DC 
maturation and migration were decreased compared to wild-type in response to tumor 
material, and their induction of a T cell response was much weaker. For our desired 
therapeutic outcome of increasing dendritic cell-mediated antitumor immunity, 
augmented miR155 expression is the goal. Thus a total body transgenic model of miR155 
overexpression was generated on a C57BL/6 background and was confirmed to express 
increased levels of functional miR155. Bone marrow cells from these transgenic mice 
(miR155tg) and wild-type mice were harvested and differentiated into DCs by treating 
with GM-CSF and IL-4 for 8 days. At the end of this differentiation period, flow 
cytometry confirmed that >80% of the cells were CD11c+, >95% of the cells were 
CD11b+, and <5% of the cells were Gr1+ (Figure 5.1A). These cells were considered 
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immature DCs. In order to mature them and gage the effects of their exposure to tumor 
antigen, immature wild-type and miR155tg DCs were each divided into two groups. One 
of which was treated with EO771 tumor-conditioned medium (ECM) and EO771 tumor 
cell lysate, the other was treated only with the corresponding medium as a control. Our 
results show that miR155tg DCs pulsed with tumor material in this way exhibit higher 
expression of MHCII, CD80, and CD86 than wild-type cells (Figure 5.1B). Interestingly, 
CD40 appeared to be expressed at a lower level in miR155tg DCs. CCR7 expression, 
which our lab has shown is linked to miR155, is drastically increased in both tumor 
antigen-pulsed and naïve miR155tg DCs (Figure 5.1C). Overall, these results point to a 
likely increase in miR155tg DCs’ capacity to both reach lymph nodes, and once there to 
activate T cells. In vivo assessment of DC maturation in the spleens, lymph nodes, and 
tumors of mice transplanted with either miR155tg or wild-type bone marrow yielded 
similar results (Figure 4.3). Thus over-expression of miR155 in DCs does appear to 
increase maturation upon exposure to breast cancer antigens both in vitro and in vivo.  
miR155tg dendritic cells exhibit increased migration in vitro and in vivo 
The observation of increased CCR7 expression on miR155tg DCs is a strong 
indication that their migratory ability may be increased. A trans-well migration assay was 
performed using a gradient of CCL19 on control and tumor-pulsed wild-type and 
miR155tg DCs. Wells containing no CCL19 were used to gage the baseline levels of 
migration for each genotype and treatment condition. The results of this in vitro 
experiment mirrored the CCR7 expression results (Figures 5.2A). Transgenic DCs 
migrated to a much greater extent than wild-type under both treatment conditions. In fact, 
the migration of control-treated miR155tg DCs was greater than wild-type cells pulsed 
135 
 
with tumor antigen. Interestingly, miR155tg DCs exhibited less baseline, random 
migration but were much more responsive to CCL19 (Figure 5.2B).  
In vivo DC migration was also tested by introducing wild-type and miR155tg 
tumor antigen-pulsed DCs, which had been labeled with CFSE dye, into the groins of 
wild-type mice bearing EO771 tumors. DCs were given two days to migrate, at which 
time the draining lymph nodes were removed. Mice receiving no DCs served as negative 
controls for identifying CFSE+ cells. Results showed that CFSE+ DCs of both genotypes 
arrived at the draining lymph nodes, and there was a trend toward miR155tg DCs having 
migrated to a greater extent, but the difference was not statistically significant (Figure 
5.2C). The small number of mice per group (3) may have contributed to this null result. 
However, taken together, these data suggest that miR155 expression levels directly 
correlate with the ability of DCs to migrate in response to lymph node chemoattractants.  
miR155tg dendritic cells elicit increased T cell activation in vitro and in vivo 
In response to the observed increase in maturation marker expression on 
miR155tg DCs, it should follow that T cell activation and proliferation would also 
increase. To determine if this was indeed the case, splenic T cells from healthy, wild-type 
mice were co-cultured with miR155tg and wild-type DCs pulsed with tumor antigen. By 
analyzing T cell surface expression of CD69 and internal expression of IFNγ, we 
determined that miR155 overexpression led to significant increases in CD4+ and CD8+ T 
cell activation with IFNγ expression also increased in CD8+ T cells (Figures 5.3A&B).  
 T cell proliferation in response to this DC co-culture was also tested by staining 
the naïve T cells with CFSE and determining the decrease in fluorescence due to division. 
Our results show that T cells proliferate significantly more in response to DCs pulsed 
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with tumor antigen for both genotypes, and that miR155tg DCs induce more T cell 
proliferation than wild-type DCs, whether naïve or antigen pulsed (Figure 5.3C).  
 It is important to determine whether these T cell activation results can be 
replicated in vivo for the sake of therapeutic relevance. This was done by administering 
tumor antigen-pulsed wild-type and miR155tg DCs subcutaneously into the groins of 
wild-type, EO771 tumor-bearing mice. CD69 expression was used to define both CD4+ 
and CD8+ activated T cells. T cell activation in tumors, spleens, and tumor-draining 
lymph nodes was determined to be increased in mice that received miR155tg DCs 
compared to wild type and no DC controls (Figures 5.3D&E). This increased activation 
was present in both CD4+ and CD8+ T cells in most tissues. It was also noted that spleen 
and tumor-draining lymph node cellularity was increased in mice receiving miR155tg 
DCs (Figure 5.3F). Given the increased T cell activation in vivo and in vitro, this change 
in the numbers of lymph node and spleen cells is likely due to an augmented antitumor 
immune response initiated by the introduction of mature miR155tg DCs.    
miR155tg dendritic cells reduce systemic immune suppression 
Apart from assessing T cell activation, several other immune cell populations 
were analyzed. These were intended to provide a broader picture of the immune 
phenotype brought about by the introduction of miR155tg and wild-type DCs to tumor-
bearing mice. Spleen DC maturation, which was determined by MHCII expression, was 
significantly higher in mice inoculated with miR155tg DCs than both wild-type DC and 
no DC groups (Figure 5.4A). Tumor draining lymph node DCs also expressed more 
MHCII in miR155tg vaccinated mice than wild-type or no DC control mice (Figure 
5.4B). It is likely that a portion of these DCs are those that were injected, but given 
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previous tracking of DCs implanted in the same way, it is more likely that the vast 
majority of these cells were the mice’s own. Macrophages were more abundant in the 
tumors of mice that received no DCs than either of the DC-inoculated groups (Figure 
5.4C). Macrophage abundance is an important and generally negative prognostic 
indicator in breast cancer [210]. There was also an abundance of myeloid-derived 
suppressor cells (MDSCs) in the tumors of non-DC injected mice, here identified as 
CD11b+Gr1+ (Figure 5.4D). Significant increases in these two cell populations brought 
about an overall increase in tumor CD45+ cells (Figure 5.4E). These data suggest that, in 
this case, only two injections of tumor antigen pulsed DCs can bring about a robust and 
systemic increase in immunologic tone, and this is significantly augmented by miR155 
overexpression in the implanted DCs.  
miR155 overexpression increased the efficacy of a dendritic cell-based vaccine for breast 
cancer 
To investigate the potential therapeutic efficacy of the miR155-overexpressing 
DC-based cancer immune therapy, a therapeutic vaccine strategy was implemented in 
mice bearing EO771 breast tumors. These mice received tumor antigen-pulsed wild-type 
or miR155tg DCs twice per week for 3 weeks. Another group of mice received injections 
of only PBS on the same schedule as a vehicle control. Tumor growth was monitored 
during this vaccination period and for 19 days after (Figure 5.5A). Tumor growth was 
significantly inhibited in both DC vaccine groups, but miR155tg DC-vaccinated mice 
exhibited more suppressed tumor growth than those receiving wild-type DC vaccination 
(Figure 5.5B). It was clear from the examination of mice shortly after receiving DC 
injections, that DC miR155 overexpression could induce a significant increase in T cell 
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activation. In this study we wanted to see if this gain in immune function could be 
maintained for a significant period after the full course of the vaccine was administered. 
With the intent of such therapeutic vaccines being to boost specific and systemic 
antitumor immunity, it would be advantageous for the treatment to bring about a 
sustained immune response focused on the primary tumor as well as distant metastases. 
At the time of sacrifice, 19 days after the administration of the last vaccine injection, 
miR155tg DC-vaccinated mice exhibited lower average tumor weight than mice that had 
received no DCs, while wild-type vaccinated mice did not maintain this difference 
(Figure 5.5C). Tumor draining lymph node weight and cellularity were also higher in 
miR155tg DC-vaccinated mice (Figure 5.5D). Cytotoxic T cells (CD8+IFNγ+) were also 
more abundant in the tumors, spleens, and tumor-draining lymph nodes of miR155tg DC-
vaccinated mice than non-vaccinated mice (Figure 5.5E). Cytotoxic T cell frequency at 
least trended higher in miR155tg DC-vaccinated mice than mice that received wild-type 
DCs (Figure 5.5E). Tumor DC MHCII also remained higher in miR155tg vaccinated 
mice. It is somewhat possible, but unlikely that any of these DCs were the ones 
introduced in the vaccine injections after 19 days (Figure 5.5F). Taken together, these 
data show that a systemic elevation in immunologic tone is maintained for an extended 
period after vaccination has ended. This immune response as well as the 
contemporaneous effects of the vaccine leading to decreased metastasis are important 
indicators of its therapeutic potential.  
5.4 DISCUSSION 
 Our data revealed that overexpression of miR155 in DCs increased maturation in 
response to tumor-produced cytokines and antigen. CCR7 expression was also increased 
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in agreement with our previous results in miR155-/- animals. This increase in CCR7 
expression yielded an increase in the migratory response of DCs to CCL19, a key 
cytokine produced by high endothelial venules and T cell zones in lymph nodes to attract 
antigen-loaded DCs [211]. DC-induced T cell activation and proliferation were also 
significantly increased by DC overexpression of miR155. The injection of miR155tg DCs 
into EO771 tumor-bearing mice resulted in a more pronounced decrease in systemic 
tumor-induced immune suppression than the injection of wild-type DCs. This was 
observed as an increase in tumor, spleen, and tumor-draining lymph node DC activation, 
as well as dramatic decreases in tumor MDSCs and macrophages. Finally, 
implementation of a basic DC vaccination regimen in an orthotopic model of metastatic 
murine breast cancer showed that DC miR155 overexpression was able to improve the 
vaccine’s capability to slow primary tumor growth and maintain antitumor immunity 
long after the last vaccine injection had been administered. Our DC vaccine regimen does 
not employ any additional maturation stimulants, such as TLR4 ligands or TNF-α due to 
the fact that our objective here is not to implement the maximally matured DC vaccine, it 
was to study the effects of miR155 overexpression on DC maturation and resulting 
antitumor immunity. Taken together, these data support the conclusion that 
overexpression of miR155 significantly increases the efficacy of DC vaccines targeting 
breast cancer, and that such a regulatory manipulation may improve the prospects of 
developing effective DC-based immune therapies for human breast cancer.   
 A number of previous studies have been focused on the role of miR155 in a wide 
variety of DC functions from development to apoptosis to immune activation [161, 186]. 
Depending on the focus of the study, miR155 has been linked to everything from 
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hampering immune function to improving it to a beneficial or even pathological degree 
[180, 212, 213]. Previous models of miR155 overexpression have been based on either 
Cre-Lox recombination or viral overexpression. Some such models have shown that 
increased DC miR155 led to increased apoptosis upon activation, though based purely on 
viability we did not observe this, and even if apoptosis was increased to some degree, this 
did not seem to effect the outcomes of increased T cell activation or antitumor immunity 
induction [186]. Many studies, however have demonstrated that miR155 is upregulated 
upon treatment with various maturation-inducing ligands, most commonly LPS [185, 
186, 214]. However, some studies have reported no difference in LPS-induced DC 
maturation (expression of CD40, CD80, CD86, and MHCII) when miR155 is knocked 
down or even completely knocked out [161, 186]. Even without this difference in 
maturation markers, impaired T cell activation was observed [185]. Our previous work 
focused on inducing DC maturation using only tumor-derived material, not LPS, and we 
found that lack of miR155 resulted in both significantly impaired maturation and 
subsequent T cell activation as well as augmented tumor growth.  
One way in which increasing DC miR155 expression has been found to have a 
potentially deleterious effect on proper antigen presentation is through indirectly 
decreasing the expression of the C-type lectin DC-SIGN, a molecule capable of binding 
high mannose-containing glycoproteins present on viruses, bacteria, fungi, and tumor 
cells [212, 215-217]. It has been shown that APCs such as DCs interact with tumor 
glycoproteins such as MUC-1 [215]. The status of DC-SIGN as a Pattern-Associated 
Molecular Pattern receptor (PAMP) has also led to its targeting in some cocktails 
intended to stimulate DCs for therapeutic and preventative vaccination [218-222]. This 
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decrease in DC-SIGN expression occurs physiologically over the course of DC 
maturation, during which antigen uptake decreases and mir155 expression increases 
[212]. However, our results show that DC-SIGN is actually expressed to a higher degree 
on miR155tg DCs than wild-type (Figure 5.6A), and the net effects of increasing DC 
miR155 generally increased the ability of DCs to foster an antitumor immune response. It 
has even been shown that miR155 suppresses IL-1 expression in DCs during maturation 
[180]. It is possible that this is to prevent potentially damaging level of inflammatory 
cytokine production while still inducing an effective immune response. Our data show 
that miR155tg DCs do indeed express much less IL-1β in response to tumor material than 
wild-type DCs (Figure 5.6B).  
Overall, the balance between immune activation and suppression by miR155 was 
tipped in the direction of increased DC maturation and T cell activation due to its 
multiple directly immune stimulatory effects, some of which we have confirmed in our 
model. Suppressor of cytokine signaling 1 (SOCS-1) is a direct target of miR155 and has 
been shown to regulate the production of IL-12, a key cytokine necessary for the 
complete activation of T cells and other immune cells with which DCs interact [186]. 
Overexpression of miR155 in DCs increased IL-12p70 expression, and thus increased 
IFNγ production in co-cultured NK cells [186]. We found that SOCS-1 expression was 
decreased in our miR155tg DCs, consistent with these previous results (Figure 4.1E), 
and that IL-12β subunit expression was increased compared to wild-type DCs upon 
tumor exposure (Figure 5.6B). The transcription factor component c-Fos has also been 
shown to be a direct target of miR155 in DCs [185]. Transcription factor complexes 
containing c-Fos were shown to suppress DC maturation, thus miR155 blocks this 
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suppression and facilitates DC activation. Our miR155tg DCs also exhibited decreased c-
Fos expression and increased maturation in response to tumor material (Figure 5.6B).  
Though there is still debate regarding the complex roles of miR155 in DC 
development, maturation, and immune activation, it is clear that miR155 is an important 
regulator of DC biology. It has been shown that miR155 directly influences a network of 
other microRNAs in DCs in addition to the many functions described previously [223]. In 
our model of miR155 transgenic overexpression, the net result was increased DC 
maturation, T cell activation and proliferation, and increased migration in response to 
lymph node chemoattractants. Use of these DCs in a breast cancer therapeutic 
vaccination resulted in decreased tumor growth and tumor-induced immune suppression. 
These results, as well as the regulatory activities of miR155 described in previous 
literature, suggest that forced overexpression of miR155 may enhance the therapeutic 













Table 5.1 Antibodies for flow cytometry 
Antibody Product # Company 
CD45 (PE-Cy7) 103113 Biolegend 
CD11b (FITC) 101205 Biolegend 
CD11c (APC) 117309 Biolegend 
CD11c (FITC) 117305 Biolegend 
Gr1 (PE) 108407 Biolegend 
I-A/I-E (APC-Cy7) 107627 Biolegend 
CD40 (PE) 124609 Biolegend 
CD80 (FITC) 104705 Biolegend 
CD86 (APC) 105011 Biolegend 
CCR7 (PE) 120105 Biolegend 
CD3 (APC-Cy7) 100221 Biolegend 
CD4 (APC) 100411 Biolegend 
CD8 (FITC)  100803 Biolegend 
CD69 (PE) 104507 Biolegend 
IFNγ (PE) 505807 Biolegend 
F4/80 (PE) 123109 Biolegend 
DC-SIGN (PE) 833003 Biolegend 
 
Table 5.2 Primers for RT-qPCR 
Primer Product # Company 
U6 MS00014000 Qiagen 
miR155 MS00001701 Qiagen 
Primer Forward Reverse 
18s CGCGTTTCTATTTTGTTGGT AGTCGGCATCGTTTATGGTC 
CCR7 GCTTCTGCCAAGATGAGGTC CCACGAAGCAGATGACAGAA 
IL-12β GAGAAGGTCACACTGGACCA TGACCTCCACCTGTGAGTTC 
IL-1β GCCCATCCTCTGTGTGACTCAT AGGCCACAGGTATTTTGTCG 







Figure 5.1 Dendritic cell maturation is promoteded by miR155 overexpression. A, 
Representative flow cytometry dot plots showing the results of bone marrow DC 
differentiation with 20 ng/mL GM-CSF and 20 ng/mL IL-4. B, miR155tg and wild-type 
DCs were pulsed with tumor material, stained for maturation markers (MHCII, CD40, 
CD80, and CD86), and analyzed with flow cytometry. C, CCR7 epression on tumor-
pulsed DCs was also analyzed. Results are shown as means ± SE (n=3). *p<0.05, 







Figure 5.2 miR155tg dendritic cells exhibit increased migration in vitro and in vivo. 
A, Wild-type and miR155tg DCs were pulsed with tumor material, then exposed to a 
CCL19 gradient. Migration in response to CCL19 through a trans-well insert was 
quantified and representative images are shown. B, This experiment was also performed 
without the CCL19 gradient. Results are shown as means ± SE (n=3). **p<0.01. C, 
Migration of CFSE-stained, tumor-pulsed DCs in vivo to tumor-draining lymph nodes. 





















Figure 5.3 miR155tg dendritic cells elicit increased T cell activation in vitro and in 
vivo. Wild-type and miR155tg DCs were pulsed with tumor antigen, then co-
cultured with naïve wild-type T cells. A and B, After 48 h of co-culture, T cells were 
stained for CD3, CD4, CD8, CD69, and IFNγ, then analyzed using flow cytometry. C, 
Some naïve T cells were stained with CFSE prior to co-culture; after 120 h of co-culture, 
T cell CFSE fluorescence was analyzed using flow cytometry. Results are shown as 
means ± SE (n=3). *p<0.05, **p<0.01, ***p<0.005. D and E, Tumor-bearing wild-type 
mice were s.c. injected twice with wild-type or miR155tg tumor-pulsed DCs. Tumors, 
spleens, and tumor draining lymph nodes were then harvested, dissociated to a single cell 
suspension, and stained with CD45, CD3, CD4, CD8, and CD69 antibodies. Stained cells 
were analyzed using flow cytometry. F, Spleen and tumor-draining lymph node 
cellularity after 2 tumor pulsed DC s.c. injections. Results are shown as means ± SE 


















Figure 5.4 miR155tg dendritic cells reduce systemic immune suppression. Tissues 
collected for in vivo T cell activation analysis shown in Figure 5.4 were also stained for 
other immune cell populations; spleens and lymph nodes were stained with CD11c and 
MHCII antibodies; tumors were stained with CD11b, F4/80, and Gr1 antibodies. A, 
Spleen DC maturation represented by the extent of MHCII staining on CD11c+ cells. B, 
Lymph node DC maturation represented by the extent of MHCII staining on CD11c+ 
cells. C, Tumor macrophages (CD11b+F4/80+). D, Tumor MDSCs (CD11b+Gr1+). E, 
Total immune cells in tumors (CD45+). Results are shown as means ± SE (n=6-7). 
























Figure 5.5 miR155 overexpression increased the efficacy of a dendritic cell-based 
vaccine for breast cancer. A, Timeline of this experiment. 7 week-old, female C57Bl/6 
mice were implanted with 2x105 EO771 cells in each of the 4th pair of mammary fat pads. 
Beginning the following day and continuing for 3 weeks, mice received twice-weekly s.c. 
injections of tumor-pulsed wild-type or miR155tg DCs; mice were sacrificed 38 days 
after tumor implantation. B, Tumor growth. C, Tumor eight at sacrifice. D, Lymph node 
weight and total cells at sacrifice. E, T cell activation in tumors, spleens and tumor-
draining lymph nodes was determined by staining for CD45, CD3, CD4, CD8, CD69, and 
IFNγ on single cell suspensions and performing flow cytometry. F, Tumor and lymph 
node dendritic cell maturation was determined by staining for CD11c and MHCII on 
single cell suspensions and performing flow cytometry. G, Percentages of original 20 
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mice in each group that developed tumors after EO771 cell implantation. Results are 






Figure 5.6 Effects of miR155 transgenic overexpression on molecules relevant to 
dendritic cell function. A, Wild-type and miR155tg DCs were pulsed with EO771 tumor 
lysate and conditioned medium, then stained for CD11c and CD209 (DC-SIGN) and 
analyzed using flow cytometry. B, Wild-type and mir155tg DCs were treated as in A; 
RNA was then extracted and qPCR performed for mir155 and genes relevant to DC 
biology that have been linked to miR155 by previous studies. Results are shown as means 






CONCLUSIONS AND FUTURE WORK 
 The potential benefits of immune therapies for breast cancer are now beginning to 
be realized for patients. Stand-alone therapies focusing on well-defined tumor antigens, 
such as HER2, have been combined with more traditional therapeutic strategies such as 
systemic chemotherapy, other immune stimulatory agents, and even radiation [224-226]. 
These combination therapies are having increased success in clinical trials and will be 
important for the future of breast cancer therapy. The development and testing of new 
treatments to target tumors from different angles and a comprehensive understanding of 
the effects that these treatments have on the tumor itself, as well as the immune 
microenvironment, are important for the design of combination therapies with additive or 
synergistic effects. The major focus of cancer immune therapy has been on targeting 
therapies to the tumor via unique or overexpressed antigens or increasing the activity of 
adaptive immunity, specifically T cells. The two immune therapies described here focus 
on macrophages and DCs in the TME. These therapies may prove to be even more 
beneficial in combination with other immune or traditional therapies than on their own. 
Each of these therapies will be discussed individually, then some future studies to 
progress each toward clinical implementation will be discussed.  
6.1 EMODIN ADJUVANT THERAPY CONCLUSIONS 
Macrophages in the TME and in metastatic sites exhibit a high degree of plasticity 
both over the course of cancer progression as well as in different regions of an individual 
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tumor [227, 228]. During late stage disease, M2-like macrophages generally predominate, 
but this activation state remains plastic and is the result of a complex network of 
pathways [229, 230]. Innate immune therapies designed to address this regulatory 
network must exert change while not shifting the balance too far in a pro-inflammatory 
direction. Herb-derived compounds such as emodin often exert complex yet measured 
effects, and thus are promising to address the TME and complement existing therapies 
[231-233]. The specific mechanisms by which emodin exerts these effects are still not 
known, but it has been shown to affect a number of important proteins relevant for both 
inflammation and cancer including HER2/neu, NFκB, TNFα, PPARγ, IL-4, and TGF-β, 
just to name a few [98, 121, 234-236]. Emodin’s effects on TGF-β signaling in a variety 
of cancer cell types, including breast cancer, have been reported. Our lab, however, has 
attempted to characterize emodin’s effects on macrophages in the context of breast 
cancer, and has shown that it is capable of modulating macrophage M2-like polarization 
[103, 118]. This resulted in reduced lung metastases as well as tumor volume. The studies 
described here go further in both describing a new avenue by which emodin disrupts 
macrophage-tumor cell crosstalk and demonstrating that emodin is effective as an 
adjuvant chemotherapy. We show that emodin is capable of reducing macrophage TGF-β 
production and reducing the effects of TGF-β (and macrophage-conditioned medium 
containing secreted TGF-β) on tumor cell EMT. Such a relationship between 
macrophage-secreted TGF-β and tumor cell EMT has been established in a number of 
tumor models [237, 238]. As a result of these effects on tumor cells, and importantly 
macrophages subjected to tumor-secreted cytokines, emodin was able to reduce 
metastatic recurrence when administered as an adjuvant therapy following tumor 
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resection. In this adjuvant therapy model, migratory DCs were increased and Tregs were 
decreased in metastatic site-draining lymph nodes of mice treated with emodin. Both of 
these components of the tumor-bearing host’s immune phenotype have been linked with 
reduced TGF-β signaling. This is the first time that emodin has been shown to be an 
effective adjuvant cancer immunotherapy, increasing its potential effectiveness in similar 
regimens of human breast cancer treatment. 
6.2 EMODIN ADJUVANT THERAPY FUTURE WORK 
Though these data are promising, there are some questions that remain 
unanswered which may be beneficial to address and some additional work that remains to 
be done. Pertaining to the connection between adjuvant emodin therapy and increased 
recurrence-free survival, while we have demonstrated a mechanistic link between the 
metastatic site immune phenotype and the known effects of TGF-β, this connection 
should be more firmly established. If our hypotheses are correct, knockdown of TGF-β 
should diminish emodin’s effect in our orthotopic tumor resection model. This 
knockdown in vivo could be achieved through crossing TGF-β-flox mice with a relatively 
macrophage-specific Cre model such as the readily available LysM-cre or murine CD68-
cre mice, the latter of which may prove to be more specific [239]. In vitro studies 
employing the addition of a TGF-β-neutralizing antibody to macrophage-conditioned 
medium or non-contact co-cultures with tumor cells could demonstrate the same effect 
[240].  
In addition to more firmly establishing this connection, moving beyond 
demonstrating broadly that emodin inhibits metastatic recurrence when treatment is 
initiated after surgery and determining whether emodin has a more significant effect on 
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tumor cells or cells in the lung pre-metastatic niche. This could be accomplished by 
performing a group of experiments based on some form of intravenous injection of breast 
cancer cells and monitoring lung metastasis formation with emodin treatment of either 
tumor cells, mice prior to tumor cell implantation, or tumor-bearing mice.  
An additional relationship between lung macrophages, extravasating tumor cells, 
TGF-β, and emodin involves macrophage CXCR4 expression. It has been known that 
perivascular macrophages play a significant role in local tumor recurrence, and that this is 
at least in part due to M2-like TAMs, which express high levels of CXCR4 [241]. 
CXCR4 expression is also dependent on TGF-β, which is produced at relatively high 
levels by tumor-exposed macrophages and tumor cells [242, 243]. CXCR4 interacts with 
CXCL12, which is produced by perivascular fibroblasts at especially high levels in 
metastatic sites such as lung, liver, and bone [244]. It has recently been shown that 
CXCR4+ macrophages interact with motile tumor cells and facilitate their extravasation 
into the surrounding tissue [242]. Given that we demonstrate here that emodin is capable 
of interfering with tumor cell-macrophage TGF-β crosstalk on several levels and 
reducing M2 polarization of macrophages, which is closely linked to CXCR4 expression, 
it is likely that this mechanism is at play in our model of adjuvant emodin therapy to 
prevent metastatic recurrence.   
6.3 MIR155TG DENDRITIC CELL VACCINE CONCLUSIONS 
The second immune therapy tested focuses on DCs and their potential 
implementation in therapeutic vaccines for breast cancer. Though they seemed to show 
great promise only recently, there have been many obstacles to the development of 
effective DC vaccines. Said difficulties have often been attributed to a few crucial 
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factors. First, many such therapeutic vaccine trials only involved patients with very 
advanced disease. The second major issue with DC vaccines centers on the immune 
suppression induced by the tumor for purposes of self-preservation. Additional and 
lasting immune activation of DCs is necessary to overcome this when reintroduced into 
the patient. TLR agonists such as LPS are effective maturing agents for DCs prepared ex 
vivo as therapeutic vaccines. However, maturation with ligands such as these is more 
vulnerable to anti-inflammatory cytokines, such as IL-10, present upon re-introduction to 
the patient than strategies involving costimulatory receptor ligation or genetically forced 
upregulation of maturation [245, 246]. It is for this reason that we have focused on 
increasing the maturation of DCs via miR155. Our previous results have shown that 
miR155 deficiency impairs DC maturation and leads to increased breast cancer 
progression. The next step was to develop a stable miR155 overexpression model, then 
test the effects of miR155 overexpression on DCs and use these cells in a DC therapeutic 
vaccine model for breast cancer. We generated a novel, total body miR155 transgenic 
overexpression mouse line and used the bone marrow from these mice for both bone 
marrow transplantation and to generate DCs for in vitro testing and breast cancer 
vaccination. miR155 has been shown to generally increase the activation of a variety of 
pro-inflammatory immune cells while at the same time reducing the activity of 
tolerogenic cell populations [247]. Bone marrow transplantation followed by orthotopic 
tumor implantation allowed for the comparison of several of these cell types’ responses 
between wild-type and miR155tg immune systems. The results largely pointed to an 
increase in systemic immune activation, especially DC activation and presence, as well as 
an increase CD8+ T cell activity. Further testing of miR155tg DCs in vitro revealed 
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increased CD86, MHCII, and CD80 expression upon exposure to tumor material. Co-
culture of these DCs with T cells increased T cell activation and proliferation. miR155tg 
DCs also exhibited higher CCR7 expression and a corresponding increase in migration in 
response to CCL19. Introduction of ex vivo matured miR155tg DCs into breast tumor-
bearing mice reduced tumor growth and augmented antitumor immunity to a greater 
extent than wild-type DCs. This effect persisted for many days after the last DC 
inoculation was administered and resulted in a lower lung metastatic burden. These data 
show that at least some method of delivering miR155 to DCs of immune cells more 
broadly in the TME would be a beneficial strategy to pursue.  
6.4 MIR155 DENDRITIC CELL VACCINE FUTURE WORK 
The project focusing on the effects of miR155 in DCs and the development of a 
miR155-overexpressed DC vaccine requires less additional work, but the development of 
the miR155tg mouse model opens up many possibilities. Not only could a much more 
detailed understanding of the regulatory changes brought about by stably increasing 
miR155 expression in DCs be gained, but also in many other cell types, both immune and 
otherwise. The majority of what is known about the many roles or miR155 has been 
gained by making use of miR155-/- mice. Virally introduced overexpression often ends up 
affecting only a small percentage of certain cells and is a more invasive method than 
constitutive overexpression. This model could provide the corresponding overexpression 
side to the many miR155-/- experiments, which is necessary to more firmly establish the 
previously described roles of miR155 and those yet to be uncovered.  
Both of these potential therapies still require further testing in order to develop 
delivery methods that are more readily translatable to patients. It also may prove fruitful 
159 
 
to combine these methods with other immune therapies or more traditional 
chemotherapies. The added focus on treating the immune component of diseases is being 
seen as more valuable, and this is particularly the case with cancers. The results of these 
studies point to both emodin and miR155 as important potential additions to the 
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